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A B S T R A C T
Background
Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, but the treatments
often result in dysphagia (a difficulty in swallowing) as a side effect. This may be acute, resolving after treatment, or remain as a long-
term negative sequela of head and neck cancer (HNC) treatment. Interventions to counteract the problems associated with dysphagia
include swallowing exercises or modification of diet (bolus texture, size), or both.
Objectives
To determine the effects of therapeutic exercises, undertaken before, during and/or immediately after HNC treatment, on swallowing,
aspiration and adverse events such as chest infections, aspiration pneumonia and profound weight loss, in people treated curatively for
advanced-stage (stage III, stage IV) squamous cell carcinoma of the head and neck.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Cochrane Central Register of Controlled Trials (CEN-
TRAL 2016, Issue 6); MEDLINE; PubMed; Embase; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; Web of Science; Clini-
calTrials.gov; ICTRP; speechBITE; Google Scholar; Google and additional sources for published and unpublished trials. The date of
the search was 1 July 2016.
Selection criteria
We selected randomised controlled trials (RCTs) of adults with head and neck cancer (stage III, stage IV) who underwent therapeutic
exercises for swallowing before, during and/or immediately after HNC treatment to help produce safe and efficient swallowing. The
main comparison was therapeutic exercises versus treatment as usual (TAU). Other possible comparison pairs included: therapeutic
exercises versus sham exercises and therapeutic exercises plus TAU versus TAU. TAU consisted of reactive management of a patient’s
dysphagia, when this occurred. When severe, this included insertion of either a percutaneous endoscopic gastroscopy or nasogastric
tube for non-oral feeding.
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Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were: safety and efficiency of oral
swallowing, as measured by reduced/no aspiration; oropharyngeal swallowing efficiency (OPSE)measures, taken from videofluoroscopy
swallowing studies; and adverse events, such as chest infections, aspiration pneumonia and profound weight loss. Secondary outcomes
were time to return to function (swallowing); self-reported changes to quality of life; changes to psychological well-being - depression,
anxiety and stress; patient satisfaction with the intervention; patient compliance with the intervention; and cost-effectiveness of the
intervention.
Main results
We included six studies (reported as seven papers) involving 326 participants whose ages ranged from 39 to 83 years, with a gender
bias towards men (73% to 95% across studies), reflecting the characteristics of patients with HNC. The risk of bias in the studies was
generally high.
We did not pool data from studies because of significant differences in the interventions and outcomes evaluated. We found a lack of
standardisation and consistency in the outcomes measured and the endpoints at which they were evaluated.
We found no evidence that therapeutic exercises were better than TAU, or any other treatment, in improving the safety and efficiency
of oral swallowing (our primary outcome) or in improving any of the secondary outcomes.
Using the GRADE system, we classified the overall quality of the evidence for each outcome as very low, due to the limited number
of trials and their low quality. There were no adverse events reported that were directly attributable to the intervention (swallowing
exercises).
Authors’ conclusions
We found no evidence that undertaking therapeutic exercises before, during and/or immediately after HNC treatment leads to im-
provement in oral swallowing. This absence of evidence may be due to the small participant numbers in trials, resulting in insufficient
power to detect any difference. Data from the identified trials could not be combined due to differences in the choice of primary
outcomes and in the measurement tools used to assess them, and the differing baseline and endpoints across studies.
Designing and implementing studies with stronger methodological rigour is essential. There needs to be agreement about the key
primary outcomes, the choice of validated assessment tools to measure them and the time points at which those measurements are
made.
P L A I N L A N G U A G E S U M M A R Y
Swallowing exercises for affecting swallowing after treatment in people with advanced-stage head and neck cancers
Review question
To establish the evidence for the effects of therapeutic swallowing exercises, undertaken before, during and/or immediately after head
and neck cancer treatment, on swallowing.
Background
A swallowing impairment (dysphagia) commonly occurs as a result of head and neck cancer treatment. It may be temporary, resulting
from a dry mouth or irritation of the lining of the mouth during treatment, or permanent due to a narrowing (stricture) of the throat
after surgery and/or radiotherapy. Undertaking swallowing exercises before, during and/or immediately after HNC treatment may
prevent dysphagia occurring, or may reduce its severity.
Clinicians who are treating dysphagia in head and neck cancer patients lack evidence-based guidelines so it is challenging to deter-
mine which interventions are suitable, but many speech and language therapists encourage patients to undertake exercises intensively
throughout head and neck cancer treatment, based on a ’use it or lose it’ principle.
Study characteristics
We included six studies with 326 participants who undertook therapeutic exercises before, during and/or after HNC treatment. We
could not combine the results of the studies because of the variation in participants’ cancers, their treatments, the outcomes measured
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and the tools used to assess them, as well as the differing time points for testing. Researchers have compared: (i) therapeutic exercises
versus treatment as usual (TAU); (ii) therapeutic exercises versus sham therapy; (iii) therapeutic exercises plus TAU versus TAU.
The therapeutic exercises varied in their design, timing and intensity. TAU involved managing patients’ dysphagia when it occurred,
including inserting a tube for non-oral feeding.
Key results
The evidence is up to date to 1 July 2016.
We found no evidence that therapeutic exercises were better than TAU, or any other treatment, in improving the safety and efficiency of
oral swallowing (our primary outcome) or in improving any of the secondary outcomes. However, there is insufficient evidence to draw
any clear conclusion about the effects of undertaking therapeutic exercises before during and/or immediately after HNC treatment
on preventing or reducing dysphagia. Studies had small participant numbers, used complex interventions and varied in the choice of
outcomes measured, making it difficult to draw reliable conclusions. There were no reported adverse events directly attributable to the
intervention (swallowing exercises).
Quality of evidence
The current quality of the evidence to support the use of therapeutic exercises before, during and/or immediately after HNC treatment
to prevent/reduce dysphagia is very low. We need better designed, rigorous studies with larger participant numbers and agreed endpoints
and outcome measurements in order to draw clear(er) conclusions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Therapeutic swallowing exercises compared with treatment as usual (TAU) for dysphagia in head and neck cancer patients
Patient or population: adults with advanced head and neck cancer
Settings: acute/ hospital departments and clinics
Intervention: therapeut ic swallowing exercises
Comparison: t reatment as usual (TAU)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Treatment as usual
(TAU)
Therapeutic swal-
lowing exercises
Swallowing func-
tion/ efficiency
Measured using a
rat ing of oropharyn-
geal swallowing ef f i-
ciency (OPSE) quan-
t if ying the interac-
t ion of the speed
of bolus move-
ment and safety/ ef -
f iciency in clearing
material f rom the
oropharynx
Dysphagia is de-
f ined as an OPSE
score of less than 39
10 weeks post-treat-
ment
N/ A N/ A 10 weeks post-treat-
ment: MD -8.06 (95%
CI -25.37 to 9.25)
16 (TAU group 8: in-
tervent ion group: 8)
(1 study)
Lazarus 2014
⊕©©©
very low1,2
Swallowing funct ion
(OPSE) improved
following treatment,
However, the ef fect
did not reach stat is-
t ical signif icance
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Adverse event:
Weight loss (> 10%)
Change in nutri-
t ional status re-
f lected by a pat ient ’s
weight measured at
6 weeks post-treat-
ment
N/ A N/ A Weight loss at 6
weeks: RR 0.62 (95%
CI 0.22 to 1.71)
27 (TAU group 13;
Pharyngocise group
14)
(1 study)
Carnaby-Mann 2012
⊕©©©
very low1,2
At 6 weeks post-
treatment, the risk of
weight loss (> 10%)
is around 40% lower
in the Pharyngocise
group compared to
the TAU group. How-
ever, the est imate
has a wide conf i-
dence interval and is
not stat ist ically sig-
nif icant
Adverse event:
Weight loss (> 10%)
Change in nutri-
t ional status re-
f lected by a pat ient ’s
weight during the
study period
10 weeks post-treat-
ment
N/ A N/ A Not est imable 55 (TAU 28; interven-
t ion group 27)
(1 study)
van der Molen 2011
⊕©©©
very low1,2
There was no com-
parison between the
intervent ion
and TAU group. Re-
sults were f rom the
pre- and post-treat-
ment scores for 49
part icipants
Adverse event:
Weight change
Patient ’s body
weight 6 months be-
fore the start of
treatment was re-
trieved f rom the
pat ient ’s medical
notes and ‘‘relat ive
weight change’’ was
calculated as the
percentage weight
change relat ive to
the weight at week 0
N/ A N/ A 6 months post-treat-
ment): MD 1.34 (95%
CI -0.46 to 3.14)
120 (intervent ion
group 60; TAU group
60)
(1 study)
van den Berg 2014
⊕©©©
very low1,2
The weight change
est imate has a wide
conf idence interval,
therefore the ef fect
is uncertain
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6 months post-treat-
ment
Aspiration
Scored as present,
trace or absent, for
any consistency
5 months post-treat-
ment
N/ A N/ A 5 months post-treat-
ment: TAU group
18.18%; intervent ion
group 7.69%
39 (TAU group 20; in-
tervent ion group 19)
(1 study)
Mortensen 2015
⊕©©©
very low1,2,3
Results were re-
ported as a percent-
age - not est imable.
Penetration
Scored as present,
trace or absent, for
any consistency
5 months post-treat-
ment
N/ A N/ A 5 months post-treat-
ment: TAU group
45.45%; intervent ion
group 23.08%
39 (TAU group 20; in-
tervent ion group 19)
(1 study)
Mortensen 2015
⊕©©©
very low1,2,3
Results were re-
ported as a percent-
age.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%
conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; M D: mean dif ference; N/ A: not applicable; OPSE: oropharyngeal swallowing ef f iciency; RR: risk rat io; TAU: t reatment as usual
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Few part icipants.
2Risk of performance bias is high (Carnaby-Mann 2012; Lazarus 2014; Mortensen 2015; van den Berg 2014) or unclear (Kotz
2012; van der Molen 2011).
3Unclear if the assessor was blinded to the intervent ion (Mortensen 2015).
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B A C K G R O U N D
Description of the condition
Head and neck cancer encompasses malignant tumours of the
upper aerodigestive tract including the pharynx, larynx, oral cav-
ity, nasal cavity, paranasal sinuses and salivary glands (Argiris
2008). Approximately 550,000 new cases are diagnosed each year
throughout the world (Jemal 2011), the majority of which are
mucosal squamous cell carcinoma (www.ncri.ie). Tobacco and al-
cohol abuse are two important risk factors associated with oral,
pharyngeal and laryngeal cancer (Blot 1988; Decker 1982). Viral
infection also plays a role (Marur 2010), with associations between
the human papilloma virus and oropharyngeal cancer (Gillison
2000; Ragin 2007), as well as the Epstein-Barr virus and nasopha-
ryngeal carcinoma (Sankaranarayanan 1998).
An individual patient’s prognosis is determined by the type and
extent of their cancer, established during staging. Head and neck
cancer staging takes into consideration anatomic subsite, tumour
size, cervical lymph node involvement and the presence of distant
metastasis (AJCC 2010; NCCN 2014). Up to 40% of patients
have early stage I and II cancer when they first present (NCCN
2014).
Treatment options include surgery, radiation and chemotherapy.
The majority of early stage I and II patients can be treated with
single modality therapy using either surgery or radiation alone,
and survival rates are similar for both types of treatment (Gregoire
2010; Higgins 2009; NCCN 2014). In contrast, when advanced
stage III and IV cancer is treated with the aim of curing the patient,
this requires multimodality therapy to include surgery with adju-
vant radiotherapy or organ preservation chemoradiation (Pignon
2009). Adjuvant chemotherapy has proven beneficial for some pa-
tients with advanced disease (Forastiere 2003). Ultimately, head
and neck cancer treatment is individualised to the patient and
based not only on the stage of the cancer and the likely prognosis
associated with that stage, but also the patient’s co-morbidities and
wishes. Sometimes treatment is palliative and not intended to try
and elicit a cure.
Description of the problem
Although survival rates from head and neck cancer have improved
overall, this has been due to more aggressive treatment so morbid-
ity has correspondingly increased. Morbidity includes dysphagia,
which may be due to the cancer itself or may occur as a result of
modern aggressive treatment(s), or both. Dysphagia ranges from
a temporary problem in swallowing (due to mucositis or xerosto-
mia during treatment) through to a more long-term or even per-
manent problem (due to fibrosis or a stricture), which results in
non-oral tube feeding being needed, using a nasogastric tube or a
percutaneous endoscopic gastrostomy.
The consequences of dysphagia are not only a reduction in food/
fluid intake, but often a reduction in people’s activity and so-
cial participation (InternationalClassificationof Functioning, ICF
2001), with corresponding negative changes to their quality of life.
In countries where much socialisation revolves around preparing
and eating food together, psychological well-being can be nega-
tively affected by dysphagia (Rappoport 2003).
Description of the intervention
Dysphagia therapy is recognised internationally as the provision
of services to patients with a difficulty in swallowing, usually by
a speech and language therapist (also known as a speech pathol-
ogist or speech therapist). Therapy may occur through using be-
havioural management procedures, principally divided into com-
pensatory strategies and direct techniques (Logemann 1999). Di-
rect techniques are the focus of this review.
Direct techniques (also known as therapeutic exercises) consist of
either swallowing or neuromuscular exercises. Swallowing exercises
are designed to change the swallow physiology by improving sen-
sory motor integration or by gaining voluntary control over the
timing or the co-ordination of selected oropharyngeal movements
during swallowing (Logemann 1999).
Neuromuscular exercises target tongue strength, endurance and/
or power. Strength is achieved by exercises that use high levels
of resistance (isometric) exercises. Endurance is achieved through
repeated performance of exercises involving low levels of resistance.
Power is achieved by using exercises that focus on the speed of
muscle contraction (Clark 2003).
How the intervention might work
Swallowing exercises are designed to improve swallowing safety (i.e.
to reduce penetration, in which a bolus (a ball of food, fluid) en-
ters the larynx at/above the vocal folds, or to reduce aspiration, in
which a bolus enters below the vocal folds into the trachea/upper
airway). Other swallowing exercises are designed to improve effi-
ciency (i.e. to increase the speed or amount of a bolus swallowed,
or both) (Logemann 1999).
Neuromuscular exercises are designed to increase tongue range of
motion and/or strength, thus indirectly improving oral bolus tran-
sit (speed and bolus clearance) as tongue force/strength is a key
component of a safe swallow. Exercises to increase tongue range
of motion are used to keep the tongue mobile during/after head
and neck cancer treatment and to mitigate against the stiffening
and fibrosis that can result from radiotherapy, surgery or both
(Appleton 1994; Fujiu 1996).
Why it is important to do this review
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Changes to HNC treatment mean that patient survival has im-
proved over the last decade, but this has been at the expense of
increased morbidity (speech, swallowing function).
Treatment nowadays promotes ’organ preservation’, which is ap-
pealing, but preservation of structure does not alwaysmean preser-
vation of function and, unfortunately, some HNC treatment reg-
imens have profound and long-lasting negative side effects. While
all HNC treatments have side effects, these are compounded when
multi-modal treatments are used, as in modern protocols (Frowen
2006).
A swallowing problem (dysphagia) is now widely accepted as both
an acute and a late toxicity after radiotherapy treatment and it
has been stated that, “the problem of swallowing dysfunction is
probably becoming one of the most important and clinically rele-
vant side-effects after curative radiotherapy or chemo-radiation.”
(Langendijk 2007, pp4).
Given the need toprevent or reduce treatment-relatedmorbidity in
order to reduce the survivorship burden for patients and families,
as well as the cost to healthcare systems, a review of the usefulness
of therapeutic exercises for affecting post-treatment swallowing
in patients treated for advanced squamous cell carcinoma of the
head and neck using Cochrane methodology was warranted. This
review is based on a published protocol (Perry 2014).
O B J E C T I V E S
To determine the effects of therapeutic exercises, undertaken be-
fore, during and/or immediately after HNC treatment, on swal-
lowing, aspiration and adverse events such as chest infections, as-
piration pneumonia and profound weight loss, in people treated
curatively for advanced-stage (stage III, stage IV) squamous cell
carcinoma of the head and neck.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). We did not plan to include
studies employing quasi-randomisation.
Types of participants
Adults with a clinical and histological diagnosis of a large (stage
III, stage IV) squamous cell carcinoma of the head and neck who
received any type of cancer treatment (surgery and radiation ther-
apy, surgery and chemoradiotherapy, or chemoradiotherapy with-
out surgery), who were deemed at risk of, or presented with, dys-
phagia (swallowing impairment). We included people with all lev-
els of dysphagia severity and we set no age limits.
Types of interventions
We included direct therapeutic techniques involving swallowing
or neuromuscular exercises or both.
Therapy programmes might be delivered before, during and/or
immediately after HNC treatment, but they must be designed
to prevent/reduce dysphagia from occurring and have lasted for
more than one session. Interventions may have been provided by
one or more health disciplines (for example, we included studies
involving only speech and language therapists (SLTs) and those
involving other healthcare professionals).
The main comparison was therapeutic exercises versus treatment
as usual (TAU).
Other possible comparison pairs included: therapeutic exercises
versus sham exercises; sham exercises versus TAU; and therapeutic
exercises plus TAU versus TAU.
Types of outcome measures
We analysed the following outcomes in the review, but they were
not used as a basis for including or excluding studies.
Primary outcomes
• Safety and efficiency of oral swallowing, as measured by:
◦ reduced/no aspiration;
◦ oropharyngeal swallowing efficiency (OPSE)
measures, taken from videofluoroscopy swallowing studies;
◦ adverse events, such as chest infections, aspiration
pneumonia, profound weight loss.
Secondary outcomes
• Time to return to function (swallowing).
• Self-reported changes to quality of life.
• Changes to psychological well-being: depression, anxiety
and stress.
• Patient satisfaction with the intervention.
• Patient compliance with the intervention.
• Cost-effectiveness of the intervention.
We assessed both short-term (three months or less) and long-term
(at, or more than, six months) outcomes.
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Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 1 July 2016.
Electronic searches
The Information Specialist searched:
• Cochrane ENT Trials Register, via the Cochrane Register of
Studies (searched 1 July 2016);
• Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 6);
• Ovid MEDLINE (1946 to June Week 4 2016);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 1 July 2016);
• Ovid Embase (1974 to 2016 week 26);
• EBSCO CINAHL (1982 to 4 July 2016);
• LILACS (searched 4 July 2016);
• KoreaMed via Google Scholar (searched 4 July 2016);
• IndMed (searched 4 July 2016);
• PakMediNet (searched 4 July 2016);
• Web of Knowledge, Web of Science (1945 to 4 July 2016);
• ClinicalTrials.gov, www.clinicaltrials.gov (searched via the
Cochrane Register of Studies 4 July 2016);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 4 July 2016);
• speechBITE (Australian speech and language therapy)
(searched 4 July 2016);
• Google Scholar (searched 4 July 2016);
• Google (searched 4 July 2016).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, TRIPdatabase,
The Cochrane Library and Google to retrieve existing systematic
reviews relevant to this systematic review, so that we could scan
their reference lists for additional trials.
Data collection and analysis
Selection of studies
Two review authors (AP and SC) independently reviewed the titles
and abstracts of the records identified from electronic searches and
immediately excluded irrelevant studies. We obtained the full text
of the remaining studies and two review authors (AP and CK)
selected studies based on the inclusion criteria of the review.Where
these authors were unsure, another review author (SC) made a
final decision. We contacted trial authors for further details and
documented the reasons for exclusion.
Data extraction and management
Two review authors (AP and CK) independently extracted study
data and recorded information on a data extraction form. We
resolved any discrepancies through discussion.We entered the data
into Review Manager (RevMan), version 5.3 (RevMan 2014). We
extracted the following from each study:
• Citation details: title, authors, source and year of
publication.
• Participant inclusion and exclusion criteria.
• Participant details: age, gender, location/size of tumour,
time since diagnosis, level of swallowing ability, setting.
• Recruitment details: number of people screened, eligible,
recruited and randomised, withdrawals.
• Methodological quality details (for the Cochrane ’Risk of
bias’ tool).
• Intervention details: description of intervention/exercises,
personnel involved, training of personnel, duration, dosage,
comparison intervention.
• Outcome measures: measures chosen, by whom and when
they were administered, how they were administered (in person,
via other communication technologies or by mail).
• Study results (positive, negative, equivocal results,
withdrawal).
Assessment of risk of bias in included studies
Two review authors (SHL and CK) independently assessed risk
of bias for each study, using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011), with any disagreement resolved by discussion (AP, CK and
SHL).We completed a ’Risk of bias’ table for each individual study
using the ’Risk of bias’ tool in RevMan, version 5.3 (RevMan
2014):
• random sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias); and
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• other sources of bias.
We assessed the above domains for each trial and then assigned a
judgement about the adequacy of each entry as: ’low risk’, ’high
risk’ or ’unclear risk’ of bias.
Measures of treatment effect
Three review authors (AP, CK and SHL) independently assigned
outcome measures to the health domain assessed (oral swallowing;
aspiration; adverse events; time to return to oral swallowing; qual-
ity of life; psychological well-being; patient satisfaction; patient
compliance; cost-effectiveness of intervention).
Where more than one outcome measure was used for the same
domain from the same study, we included the measure most fre-
quently used across included studies.
We conducted separate analyses for short-term (three months or
less) and long-term (at, or more than, six months) outcomes.
We calculated risk ratios (RR) and 95% confidence intervals (CI)
for dichotomous outcomes and mean differences (MD) or stan-
dardised mean differences (SMD) and 95% CI for continuous
outcomes, as appropriate.
Unit of analysis issues
The unit of randomisation in the included studies was the indi-
vidual patient.
Dealing with missing data
We did not need to contact any trial authors for missing data. As
recommended in the Cochrane Handbook for Systematic Reviews
of Interventions, we conducted intention-to-treat analyses. Where
dropouts were clearly identified, we used the denominator of par-
ticipants contributing data at the relevant outcome assessment.
Assessment of heterogeneity
We planned to pool the results to present an overall estimate of
the treatment effect, using a random-effects model. We planned
to assess heterogeneity by visual inspection of the forest plot along
with consideration of the Chi2 test for heterogeneity and the I2
statistic (Handbook 2011).
Data synthesis
We planned to conduct a meta-analysis using a random-effects
model with 95% CI using RevMan 5.3 (RevMan 2014). Due
to the heterogeneity of the studies, we could not conduct meta-
analyses of any study data.
Subgroup analysis and investigation of heterogeneity
With a sufficient number of comparable studies (four ormore), we
had planned to perform subgroup analyses to determine whether
outcomes varied according to:
• type of therapeutic exercise (swallowing and/or
neuromuscular);
• when therapeutic exercises were initiated (pre-, peri- or
post-cancer treatment);
• frequency of therapeutic exercise;
• intensity of therapeutic exercise (dosage - number of hours
of intervention);
• intervention approach (for example, retraining with a
speech and language therapist or self-directed);
• mode of delivery (face to face versus use of a brochure/
DVD);
• whether the intervention was provided by a healthcare
professional or not;
• cancer treatment modality (surgery and radiation therapy;
surgery and chemoradiotherapy; chemoradiotherapy treatment
without surgery);
• site of tumour;
• size of tumour;
• HPV status.
We were not able to conduct subgroup analysis due to the insuf-
ficient number of comparable studies.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality of evi-
dence. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high quality of evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of very low quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included two ’Summary of findings’ tables, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011).We included the following six outcomes in the
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’Summary of findings’ table: swallowing function/swallowing ef-
ficiency; weight loss; weight change; aspiration; penetration; dys-
phagia-related complications.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We retrieved a total of 714 records through database searching
which, when 267 duplicates were removed, became 445 papers.
We also identified four ongoing studies, so this became 449 pa-
pers. First level screening (removal of clearly non-relevant refer-
ences) left 25 references for further consideration (Figure 1). We
discarded 11 records after further assessment. Four studies are still
recruiting participants (Barretos Cancer Hospital 2015; Fredslund
2015; Govender 2014; van Nuffelen 2014) (see Characteristics of
ongoing studies).
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Two review authors (SC and AP) independently assessed the 10 re-
maining full-text articles and included six studies in the review.We
excluded three studies that were not RCTs (see Excluded studies)
and one that was an RCT but the post-treatment exercises were
rehabilitative, rather than designed to reduce/prevent dysphagia
from occurring (Tang 2011). The selection was discussed with the
last author (CK) who agreed with a final inclusion of six studies
for this review (Figure 1).
Included studies
We include six studies, reported as seven papers, which met the
inclusion criteria for this review (Carnaby-Mann 2012;Kotz 2012;
Lazarus 2014; Mortensen 2015; van den Berg 2014; van der
Molen 2011). See Characteristics of included studies for detailed
descriptions for each study. van der Molen 2011 also included
data from their first study in a second (follow-up) report (van der
Molen 2014 - see van der Molen 2011 for reference). All included
studies were published in English.
Design
All six included studies were randomised controlled trials where
the authors evaluated the effectiveness of a swallowing exercise
protocol on swallowing outcomes in patients treated for HNC
compared with either treatment as usual (TAU) and/or a ’sham’
intervention.
Sample sizes
The sample sizes of the included studies ranged from 23 (Lazarus
2014) to 120 adults (van den Berg 2014). Carnaby-Mann 2012
included 58; Kotz 2012 included 26; Mortensen 2015 included
44 and van der Molen 2011 included 55 participants, of whom
29 were followed up at two years (van der Molen 2014 - see van
der Molen 2011 for reference).
Settings
Three of the six studies were undertaken in the USA. The study
by Carnaby-Mann 2012 was undertaken at a university hospi-
tal cancer centre in Gainesville, Florida. Kotz 2012 took place at
Mount Sinai medical centre (tertiary care) in NewYork. The study
by Lazarus 2014 was at Mount Sinai Beth Israel Medical Centre,
New York. The Mortensen 2015 study was from Aarhus univer-
sity in Denmark. The study by van den Berg 2014 took place in
Nijmegen in the Netherlands. The study van der Molen 2011 was
from the Netherlands Cancer Institute in Amsterdam.
Participants
Age
The mean age of participants across studies did not vary widely,
typically ranging from a mean of 58 years (range 39 to 77) in
Mortensen 2015 to a mean of 63 years (range 33 to 83 years) (van
den Berg 2014), representing the population age characteristics.
Gender
Participants were predominantly male, but the sex ratio varied
across studies from 74% male (van den Berg 2014) to 95% male
(Lazarus 2014).
Head and neck cancer disease characteristics
Patients with a diagnosed head and neck cancer were recruited to
all studies but the site and size of tumours varied.
Carnaby-Mann 2012, recruited patients with a head and neck
cancer of the oropharyngeal region, confirmed by histopathol-
ogy. Kotz 2012 recruited consecutive patients, newly diagnosed
with head and neck cancer; 77% had stage IV disease. Patients
in Lazarus 2014 had stage II to IV oral and oropharyngeal can-
cers. The primary tumour location was the tonsil (48%, 11 pa-
tients), then the base of tongue (39%; nine patients), lateral pha-
ryngeal wall (9%; two patients) and soft palate (4%; one patient).
T stages ranged from II to IVB (70% were IVA). Mortensen 2015
recruited consecutive adults (< 18 years) presenting with tumours
of the larynx, pharynx, oral cavity or an unknown primary. In their
control group, 75% (15) had stage IV tumours; in the interven-
tion group 84% (16) had stage IV tumours. van den Berg 2014
recruited people with T2 to T4 tumours of the oral cavity, na-
sopharynx, oropharynx, hypopharynx or larynx. Primary tumour
sites included the oral cavity/oropharynx. T stage included 33%
(16 patients) at stage III and 67% (33 patients) at stage IV. van
der Molen 2011 recruited patients with advanced squamous cell
carcinoma (stage III-IV) of the oral cavity, larynx, oropharynx hy-
popharynx and/or nasopharynx, with 33% at stage III and 67%
at stage IV.
Primary treatments for head and neck cancer
In Carnaby-Mann 2012, patients were all planned for external
beam radiotherapy (either conventional or intensity-modulated
radiotherapy). They were able to undergo magnetic resonance
imaging (MRI) and had no history of non-oral feeding. In Kotz
2012, patients all completed seven weeks of radiation treatment.
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In Lazarus 2014, 21 patients (91%) underwent chemoradiother-
apy and two (9%) had radiotherapy alone. In Mortensen 2015,
patients were scheduled for curative radiotherapy and none had
primary surgery. In the study by van den Berg 2014, patients were
planned for curative treatment (primary or postoperatively with
chemoradiotherapy or radiotherapy). In van der Molen 2011, pa-
tients were planned for curative treatment (primary or postoper-
atively) with chemoradiotherapy or radiotherapy. There were no
studies in which patients were treated with surgery.
Interventions
Most researchers used protocols involving tongue exercises or swal-
lowing exercises, or both, but with varying regimens (in terms of
intensity and ’dosage’).
Carnaby-Mann 2012 divided participants across three groups:
controls (TAU), sham therapy (’Valchuff ’) and Pharyngocise
(intervention), whereas all other studies had two groups. Kotz
2012 allocated adults to control (TAU) and intervention groups
(five targeted swallowing exercises). In Lazarus 2014, participants
were randomised into control (traditional exercises) and interven-
tion (traditional exercise plus specific tongue exercises) groups.
Mortensen 2015 randomised participants en bloc to a control
group (TAU - receipt of individual dietary advice from a dieti-
cian) and an intervention group (range of movement and resis-
tance exercises from an occupational therapist, as well as dietary
advice from a dietician). van den Berg 2014 randomised patients
to a control group (dietary counselling) and an intervention group
(home exercises, delivered by speech and language therapists). van
der Molen 2011 randomised patients into a control (TAU) and
intervention group (three times daily use of the Therabite, a tool
for mouth and jaw stretching).
Primary outcomes
Safety and efficiency of oral swallowing
There was considerable heterogeneity in the assessment tools and
outcome measures used across the included studies. Swallow-
ing orally as a primary outcome was reported in all six stud-
ies (Carnaby-Mann 2012; Kotz 2012; Lazarus 2014; Mortensen
2015; van den Berg 2014; van der Molen 2011), but swallow-
ing safely and/or efficiently was not always documented (van den
Berg 2014). The clinical criterion standard for assessing swallow-
ing (dys)function is by use of a videofluoroscopic swallowing study
(VFSS), which occurred in five studies (Carnaby-Mann 2012;
Kotz 2012; Lazarus 2014;Mortensen 2015; van derMolen 2011).
By contrast, van den Berg 2014 used a (non-validated) water swal-
lowing velocity and volume test.
Reduced/no aspiration
In the studies by Kotz 2012, Carnaby-Mann 2012 and van den
Berg 2014 aspiration was not assessed.
Mortensen 2015 and van der Molen 2011 each used a VFSS to
assess laryngeal penetration/aspiration and a validated scale was
used to rate each swallow at each time point (Rosenbek 1996):
baseline - before treatment - in both studies, and at two, five and
13 months post-treatment in the study by Mortensen 2015 and
at 10 weeks post-treatment completion in the study by van der
Molen 2011.
Lazarus 2014 used a (non-validated) scale to rate the presence,
timing and percentage of aspiration of each bolus.
Oropharyngeal swallowing efficiency
Lazarus 2014 measured the oropharyngeal swallowing efficiency
(OPSE) of each swallow during a VFSS by calculating the percent-
age of liquid, thin and thick paste boluses swallowed (by subtract-
ing any aspirate and/or oral residue), divided by the time taken to
swallow it. Dysphagia was defined as an OPSE score of 39 or less.
Swallowing function (OPSE) was assessed from a VFSS of three
swallows each of 1 ml, 3 ml and 10 ml thin liquid barium, 1 ml,
3 ml and 10 ml thick liquid barium, and 3 ml thin paste and 3 ml
thick paste.
van der Molen 2011 assessed swallowing function (not efficiency
per se) using a surrogate measure of OPSE. From a VFSS at each
time point, contrast residue was assessed (binary rating of ’yes’
(present), or ’no’ (not present)) and site (above or below valleculae,
or both).
Adverse events
Aspiration pneumonia, chest infection, dehydration and profound
weight loss were documented by Carnaby-Mann 2012 and being
tube fed was documented by Mortensen 2015 and van den Berg
2014.
Secondary outcomes
Time to return to function (swallowing)
This was not documented in any of the studies. Lazarus 2014
assessed quality of life from a patient-completed questionnaire,
the Head & Neck Cancer Inventory (HNCI) at each time point.
There was no significant difference pre- or post-treatment.
Self-reported changes to quality of life
Kotz 2012 and van den Berg 2014 both assessed swallowing-re-
lated quality of life from the ’Eating in Public’ subscale of the
Performance Status Scale for Head and Neck Cancer (PSS-HN),
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which documents a patient’s ability to share a meal with others
and in what environment (which is an indicator of swallowing
performance, not quality of life). Although self-reporting was not
used, quality of life was assessed by Lazarus 2014 using theHNCI,
by Mortensen 2015 using the EORTC, the QLC-C30 and H&
N 36 (all validated tools) and van der Molen 2011 used a ’study-
specific’ (non-standardised) questionnaire to evaluate quality of
life.
Lazarus 2014 assessed quality of life from a patient-completed
questionnaire, the HNCI, at each time point.
Changes to psychological wellbeing: depression, anxiety and
stress
Changes to patients’ psychological wellbeing were not measured
in any study.
Patient satisfaction with intervention
Patient satisfaction was not documented in any study.
Patient compliance with intervention
Carnaby-Mann 2012, Lazarus 2014 and Mortensen 2015 each
included patients’ self-report of compliance with the protocol.
Adherence to the protocol and gender differences were recorded
by the study speech pathologist in van der Molen 2011.
Cost-effectiveness of intervention
Only in the study by van der Molen 2011 (reported in van der
Molen 2014) was a cost-benefit/economic evaluation reported.
Excluded studies
We excluded three studies from the review because, despite the
study titles, in none of the studies were the participants ran-
domised (Carroll 2008; Virani 2013; Zhen 2012). We excluded
one study because, although it was an RCT, the exercises were re-
habilitative, rather then preventative, of dysphagia (Tang 2011).
See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2 for a ’Risk of bias’ graph, which illustrates our judge-
ments about each ’Risk of bias’ item, presented as percentages
across all included studies and Figure 3 for a ’Risk of bias’ sum-
mary of our judgements about each ’Risk of bias’ item for each
included study.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation (selection bias)
In all included studies the authors describe randomisation, but the
level of description of allocation varied. In four papers, computer-
generated randomisation was described (Carnaby-Mann 2012;
Lazarus 2014; van den Berg 2014; van der Molen 2011), which
means a low risk of bias. We classified the other two studies as
having an unclear risk of bias for this domain.
Allocation concealment (selection bias)
Carnaby-Mann 2012 described the randomisation schedule being
held remotely from the study environment (low risk of bias), but
the other five studies gave no detail about allocation sequence
concealment (unclear risk of bias).
Blinding
Blinding of participants and personnel (performance bias)
In only one study were the participants blinded to their inter-
vention, not knowing whether they were assigned to an inter-
vention (’Pharyngocise’) or to a sham exercise (’Valchuff ’) group
(Carnaby-Mann 2012). We classified this as a low risk of bias. In
all other studies the participants knew to which group they were
assigned (high risk of bias).
Blinding of outcome assessment (detection bias)
In three studies there was single-blinding of an assessor to the in-
tervention (low risk of bias) (Carnaby-Mann 2012; Kotz 2012;
Lazarus 2014). In the study by Mortensen 2015 there was par-
tial blinding, as the radiologist (scoring primary outcomes) was
blinded (low risk of bias), but the occupational therapist who
scored the secondary outcomes was not blinded (high risk of bias)
so we judged this study as having an unclear risk of detection bias.
The study by van der Molen 2011 had an unclear risk of bias and
van den Berg 2014 stated that there was no concealment (high
risk of bias).
Incomplete outcome data
All authors described, and gave reasons for, dropouts and for
missing outcome data (Carnaby-Mann 2012; Kotz 2012; Lazarus
2014;Mortensen 2015; van den Berg 2014; van derMolen 2011).
However, in all six studies a high rate of poor compliance with
treatment was reported, resulting in a high risk of attrition bias.
Selective reporting
Reported data were linked to pre-specified outcomes in all studies
(low risk of bias). However, van den Berg 2014 did not report
on all endpoints, as swallowing velocity and swallowing volume
tests were not reported and there was no protocol for the Carnaby-
Mann 2012 study (unclear risk of bias). We judged Mortensen
2015 tohave a high risk of bias due to discrepancy betweenplanned
and actual time point reporting.
Other potential sources of bias
Five studies had small sample sizes (low power) with the number
of participants ranging from 23 to 58 (high risk of bias), but van
den Berg 2014 had 120 participants, based on a sound sample
size calculation (low risk of bias). Timing of assessments varied.
All studies had assessment of participants at baseline (pre-treat-
ment - although it was not always specified exactly when) and
then immediately after intervention, but thereafter the times of
assessment ranged from three to six, nine and/or 11 or 12 months
post-intervention.
Compliance was self-reported by participants in the studies by
Carnaby-Mann 2012, Lazarus 2014 and Mortensen 2015 (high
risk of bias).
In the studies by Kotz 2012 and van den Berg 2014, the interven-
tion group also had weekly speech and language therapy sessions
(high risk of bias) and in Kotz 2012, 9 of 13 patients (69%) were
unable to complete the protocol (high risk of bias).
In the study by Carnaby-Mann 2012, the number and duration of
swallowing therapy sessions for patients assigned to the two treat-
ment arms were significantly greater than those for the usual care
group (F(2.81) = 4.8, P < 0.0001) (high risk of bias). The number
of sessions also differed significantly between the treatment groups
(Pharyngocise, 19.9; sham, 25.8; t = -2.194; P <= 0.03) (high risk
of bias).
van der Molen 2011 stated that patients in their control group
practised significantly more than those in the intervention group
(high risk of bias).
Lazarus 2014 measured tongue strength using an instrument of
unknown psychometric properties and it is not clear if the assessor
was blinded to the intervention (unclear risk of bias), whereas all
swallows were analysed by a blinded assessor (low risk of bias).
Given that all six studies had one or more potential sources of
bias (sample size, attrition and compliance with treatment), we
classified them all as being at high risk of bias.
Effects of interventions
See: Summary of findings for themain comparisonTherapeutic
swallowing exercises compared with treatment as usual (TAU)
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for dysphagia in head and neck cancer patients; Summary of
findings 2 Therapeutic swallowing exercises compared with sham
intervention for dysphagia in head and neck cancer patients
See: Summary of findings for the main comparison for the
main comparison ’Therapeutic exercises versus treatment as usual
(TAU)’ and Summary of findings 2 for the comparison ’Thera-
peutic exercises versus sham exercises’.
We were not able to pool data from the included studies because
of significant differences in the protocols and interventions. Such
a lack of standardisation and consistency in outcome measures is
a major barrier to assessing the effects of interventions. The low
power (due to small sample sizes), diversity of study designs and
interventions, and the potential for bias meant that we were un-
able to aggregate cross-study data. We therefore report (below) on
individual study results for the primary and secondary outcomes.
Primary outcome: safety and efficiency of oral
swallowing
Reduced/no aspiration
In the study by Lazarus 2014, at baseline seven participants aspi-
rated (five in the treatment group and two in the control group)
and there was no difference between the groups post-interven-
tion. The studies by Mortensen 2015 and van der Molen 2011
both demonstrated no significant difference between the groups
on post-treatment scores. In the study by van der Molen 2011 the
intra-observer agreement for both time points was good at 0.98
and 0.88.
Oropharyngeal swallowing efficiency: OroPharyngeal
Swallowing Efficiency (OPSE) measures
Lazarus 2014 found that the OPSE was lower (worse) than for
(previously reported) healthy controls for both groups, both be-
fore and after treatment, with marked data variability within and
across each group at both time points. At 10 weeks post-treatment
the OPSE scores in the treatment group improved; however the
difference was not statistically significant (-8.06, 95% confidence
interval (CI) -25.37 to 9.25) (see Analysis 1.1).
van der Molen 2011 achieved good agreement across two asses-
sors (0.80 and 0.89 for pre- and post-treatment group ratings re-
spectively). At 10 weeks post-treatment, the intervention group
showed significantly less residue after swallowing a solid bolus than
the control group (P < 0.02).
Adverse events
Adverse events, such as chest infections, aspiration pneumonia
and profound weight loss, were recorded in only three stud-
ies. Carnaby-Mann 2012 assessed dysphagia-related complications
(pneumonia, dehydration, mucositis and oral yeast infection) and
found no significant associations between these and the treatment
group. Weight loss was measured at six weeks post-treatment. A
total of 40% of patients (n = 23) lost more than 10% of their body
weight by six weeks post-treatment, but the average weight loss
was not significantly different across the three treatment groups
(see Analysis 4.2). Kotz 2012 had four patients discontinue exer-
cise at week five and five more discontinued after week five, due
to oral pain, throat discomfort and/or fatigue. Lazarus 2014 re-
ported that most participants were unable to continue the proto-
col during their last two weeks of treatment. Participants reported
mouth/throat pain, coughing and gagging.
Secondary outcomes
Time to return to function (swallowing)
This was not measured in any of the studies.
Self-reported changes to quality of life
Kotz 2012 found no difference between the intervention and con-
trol groups immediately post-treatment, but patients in the inter-
vention group were significantly better at three months (median
intervention score: 100, range 75 to 100 versus median control
group score: 100, range 25 to 100; P = 0.03), and at six months
later (median intervention score 100, range 75 to 100 versus me-
dian control score 100, range 25 to 100; P = 0.03). van den Berg
2014 also found no significant difference between groups using
the Performance Status Scale for Head and Neck Cancer (PSS-
HN) scale.
Lazarus 2014 found no significant difference between groups on
the Head & Neck Cancer Inventory (HNCI) after treatment.
However, the control group had a higher social disruption score
and the eating domain was significantly higher for the interven-
tion group post-treatment.
Mortensen 2015 found no significant difference between groups,
except for a lower global quality of life score at twoweeks and at two
months in the intervention group. At five, eight and 11 months
post-treatment scores were not significantly different across the
groups. van der Molen 2011 found no differences between groups
in either the pre- or post-treatment answers on the subscales of
their study questionnaire.
Changes to psychological well-being: depression, anxiety and
stress
Changes to patients’ psychological wellbeing were not assessed in
any study.
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Patient satisfaction with intervention
There was no assessment of patient satisfaction in any study.
Patient compliance with intervention
In all studies the participants had self-reported difficulties with
compliance with the protocol.
In Kotz 2012, 69% of participants discontinued the proto-
col at five weeks (due to pain from chemoradiotherapy). In
Carnaby-Mann 2012, only 68% of participants complied with a
home practice protocol. In Lazarus 2014, the treatment group had
six participants with ’poor’, two with ’fair’ and one with ’good’
compliance. Their controls had, respectively, two with ’poor’, five
with ’fair’ and four with ’good’ compliance. In the study by Kotz
2012, three patients (of 46) were excluded from analysis because
of poor compliance with the protocol, four patients discontinued
exercises after week four and five more discontinued after week
five. van der Molen 2011 reported that 51% of participants (n =
28) in their study stopped exercising after 27 days. The low com-
pliance rate in all trials is of concern when assessing results.
Cost-effectiveness of the intervention
Cost-effectiveness was reported in only one study. van der Molen
2011 examined the addition of their preventative swallowing re-
habilitation programme in improving quality-adjusted life years
(QALY) and calculated an additional cost of EUR 3200/QALY.
They state that the programme had “a higher probability of being
cost-effective compared to usual care” (p1268).
Ongoing studies
We identified four ongoing studies of the effects of therapeu-
tic exercises before, during and/or after head and neck cancer
treatment to improve oral swallowing (Barretos Cancer Hospital
2015; Fredslund 2015; Govender 2014; van Nuffelen 2014) (see
Characteristics of ongoing studies). The studies are being under-
taken in the United Kingdom (Govender 2014), Belgium (van
Nuffelen 2014), Brazil (Barretos CancerHospital 2015), andDen-
mark (Fredslund 2015). The Brazilian study has been completed,
however no results are yet available (Barretos Cancer Hospital
2015).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Therapeutic swallowing exercises compared with sham intervention for dysphagia in head and neck cancer patients
Patient or population: adults with advanced head and neck cancer
Settings: acute/ hospital departments and clinics
Intervention: therapeut ic swallowing exercises (Pharyngocise)
Comparison: sham exercises
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham exercises Pharyngocise
Adverse events:
Dysphagia- related
complications
Occurrence of dyspha-
gia-related complica-
t ions: pneumonia, dehy-
drat ion, mucosit is and
oral yeast infect ion
N/ A N/ A No data 27 (Pharyngocise group:
14;
sham group 13)
(1 study)
Carnaby-Mann 2012
⊕©©©
very low1,2
There was no compar-
ison of outcomes be-
tween the intervent ions
in the study
Adverse event:
Weight loss (> 10%)
Change in nutrit ional
status ref lected by a
pat ient ’s weight at 6
weeks af ter treatment
N/ A N/ A Change at 6 weeks
RR 0.62 (95% CI 0.22 to
1.71)
27 (Pharyngocise group:
14;
sham group 13)
(1 study)
Carnaby-Mann 2012
⊕©©©
very low1,2
At 6 weeks post-treat-
ment the risk of weight
loss (> 10%) is lower
in the Pharyngocise
group compared to the
sham group. The sham
group has less likeli-
hood of weight loss than
the Pharyngocise group.
However, the est imate
has a wide conf idence
interval, so it is not sta-
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t ist ically signif icant. The
risk of weight loss >
10% (of baseline body
weight) is around 40%
lower in the Pharyngo-
cise group compared to
the sham group
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; N/ A: not applicable; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Few part icipants.
2Risk of performance bias is high (Carnaby-Mann 2012).
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D I S C U S S I O N
This is the first systematic review to examine the evidence to sup-
port the use of therapeutic exercises before, during and/or imme-
diately after head and neck cancer (HNC) treatment to improve
oral swallowing.
Summary of main results
We assessed six included studies (reported as seven papers) but we
were not able to conduct a meta-analysis of their outcome data,
due to the heterogeneity of the participants and the variation in
study methodology.
The significant question of whether therapeutic exercises affect
post-treatment swallowing in people treated for advanced-stage
head and neck cancer cannot be answered; nor can we answer
the question of whether undertaking pre- and/or peri-treatment
exercises results in better outcomes than delaying exercise until
dysphagia becomes evident.
The lack of definitive results is mainly due to the small participant
numbers in trials, the lack of consistency in the choice of primary
outcome variables, the variation in themeasurement tools used for
assessing them, and the choice of different baseline and endpoints
across studies.
Adverse events, such as weight loss/weight change, were likely
due to the concurrent HNC treatment, rather than the result of
undertaking swallowing exercise protocols. Therewere no reported
adverse events that were directly attributable to the intervention
(swallowing exercises).
Overall completeness and applicability of
evidence
Only six studies were eligible for this review; this number was in-
sufficient to allow firm conclusions to be drawn regarding our pri-
mary outcome measure, the safety and efficiency of oral swallow-
ing. In all six studies, swallowing orally was a primary outcome,
but in only one study was swallowing safety and efficiency assessed
(Lazarus 2014).
A lack of standardisation and of consistency in reporting of out-
come measures meant that comparison of results was not possi-
ble. Due to differing study outcomes, aggregation of data was also
not possible, so no meta-analyses could be performed.We noted a
paucity of secondary outcomes measured; some were not reported
at all in any of the included studies. These included time to return
to function (swallowing), changes to psychological wellbeing and
satisfaction with the intervention. Changes to patients’ quality of
life using a self-report tool (clinical criterion standard) were re-
ported by Lazarus 2014; validated clinician-rated quality of life
measures were reported by Mortensen 2015 and a non-validated
questionnaire was reported in another study (van den Berg 2014).
In terms of patient compliance, when reported, it was unclear
how this had been recorded - whether by patient self-report or by
clinician evaluation. Either method raises potential issues of bias.
Quality of the evidence
Unfortunately, the overall quality of evidence available for this re-
view was disappointing, as all trials had small participant numbers
and were of variable methodological quality. The ’Summary of
findings’ tables indicate that all studies had low participant num-
bers - fewer than 120 (see table footnotes). We classified none of
the six studies as having a low risk of bias for all seven domains of
the Cochrane ’Risk of bias’ tool (see Figure 2 and Figure 3).
Using theGRADE (Grades of Recommendation, Assessment,De-
velopment and Evaluation) system, we classified the overall qual-
ity of evidence as very low, due to the limited number of partici-
pants in each study and the poor methodological quality of all but
one (Lazarus 2014) of the six studies reviewed (see Summary of
findings for the main comparison).
Potential biases in the review process
The review protocol was thorough and included a comprehensive
search strategy using multiple sources and an independent screen-
ing of trials for inclusion. Selection, data extraction and risk of
bias considerations were independently performed by the first and
third authors. Disagreements were resolved and confirmed by the
second and the last authors. We have presented and discussed all
outcomes described in the protocol for this review that were avail-
able for analysis, whether statistically significant or not.
The GRADE method of construction of ’Summary of findings’
tables was undertaken by the third and last review authors, and
may have been influenced by their interpretation, where ambigu-
ous or incomplete data were supplied. The first author (an expe-
rienced head and neck cancer clinician) independently examined
the ’Summary of findings’ tables and resolved any uncertainty, but
we acknowledge this could be a source of bias in the review.
Agreements and disagreements with other
studies or reviews
This is the first systematic review on this topic. Other studies
have been published in the literature where therapeutic exercises
for swallowing dysfunction were applied, but these were not ran-
domised trials and they each had very small sample sizes (Carroll
2008; Virani 2013; Zhen 2012).
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
For people with dysphagia as a result of advanced
head and neck cancer
Swallowing exercises undertaken before, during or immediately
after head and neck cancer (HNC) treatment to reduce the pos-
sibility of dysphagia developing as a treatment side effect are of-
ten suggested or implemented. However, there is currently no ev-
idence to support such advice.
For clinicians
Caution needs to be exercised in suggesting a benefit of pre- and/
or peri-treatment swallowing exercises to patients with advanced
HNC as the published evidence for efficacy is lacking, patient
compliance is poor and the question of whether such therapeutic
exercises can positively affect post-treatment swallowing in people
treated for advanced-stage head and neck cancer remains to be
answered.
Although there has been an improvement in survival rates for peo-
ple with advanced head and neck cancer, dysphagia remains as a
significant negative side effect of modern treatments (radiother-
apy or chemoradiotherapy) and there is a need to ameliorate this
outcome. To address the problem, trials of therapeutic swallowing
exercises during head and neck cancer treatment have been under-
taken, but exercise protocols vary considerably in type, amount
and delivery.
More research is needed to learn whether implementing swallow-
ing exercises before and/or during HNC treatment are justified
to reduce dysphagia as a side effect of treatment. However, before
further controlled clinical trials are implemented, pilot studies are
needed to ascertain patients’ tolerance for swallowing exercises,
and to design simple, effective swallowing exercise protocols that
can be undertaken by HNC patients at home and incorporated
into daily life, without an additional burden of attendance at a
hospital or clinic.
As there is no consensus or underpinning evidence to establish the
swallowing exercise protocols, they vary considerably and rely on
the capacity of patients to undertake them while simultaneously
undergoing intensive HNC treatment that may result in fatigue,
pain and/or mucositis. From this review, there is evidence of pa-
tients’ difficulty in complying with swallowing exercise protocols/
poor fidelity to treatment, as the protocols themselves are often
onerous to undertake. Consequently, the results are not definitive.
Well-validated tools should be used to measure key outcomes; for
example, safety and efficiency of swallowing, side effects of in-
terventions, changes to quality of life and/or to psychosocial do-
mains, and the cost-benefit of the intervention.
For policy makers
Recently published UK National Institute for Care and Health
Excellence (NICE) guidelines include the following advice
about speech and language therapy intervention, “Consider
swallowing exercise programmes for people having radiother-
apy” (NICE Guidelines 2016). Given the results of this review,
more work is needed to establish which are the effective evidence-
based interventions given by healthcare professionals who man-
age head and neck cancer patients, to identify timing, duration
and dosage, and to establish the feasibility of such ’exercise pro-
grammes’.
Rehabilitation of swallowing during and after HNC treatment
remains a significant challenge to be addressed. Until dysphagia
as a side effect of treatment is reduced, the benefit of improved
survival frommodern treatmentswill be tempered by the profound
and debilitating side effects that many patients live with.
For funders
There is an urgent need to fund quality studies to examine the use-
fulness of swallowing exercises before, during and/or after HNC
treatment in reducing/eliminating dysphagia as a profound and
debilitating side effect of HNC treatment. Collaboration across
HNC centres is needed, with agreed standards (methods and time
points) for documenting dysphagia as an adverse event. To obtain
the necessary sample sizes with such a heterogeneous patient co-
hort, multicentre (preferably international) trials need to be im-
plemented.
Feasible exercise regimes (in terms of ’dosage’ - i.e. intensity and
timing) need to be designed and rigorously assessed, to provide
good evidence to underpin and direct quality swallowing therapy.
Implications for research
General
The randomised controlled trials in this area need to be better
planned and preceded by good vanguard studies. The dropout
rate in all published trials has been unacceptably high, which has
negatively impacted on the statistical power of studies to show
positive outcomes. One reason for dropout has been the inter-
ventions used: each study has had an overly onerous exercise bur-
den for patients. Good qualitative research studies to better un-
derstand patients’ tolerance for undertaking swallowing exercises
during treatment would likely improve the design of such exercise
interventions and thereby enhance fidelity to treatment.
Design
Published studies that investigate the benefit of therapeutic swal-
lowing exercises for reducing dysphagia in people treated for ad-
vanced head and neck cancer lack methodological rigour.
Interventions need to be better designed as simple to follow, easy to
undertake exercises, and the ’dosage’ (duration, timing) of exercises
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needs to be feasible andbased on evidence of effect. To fully capture
the negative effect of dysphagia on patients’ health, applying the
World Health Organization (WHO) International Classification
of Functioning, Disability and Health (ICF) model offers a multi-
dimensional assessment to describe the effect of dysphagia on a
head and neck cancer population (Frowen 2006).
Measurement (endpoints)
The primary outcomes are not always specified: tools used to mea-
sure outcomes are not always well validated and the outcomesmea-
sured are either not variables that are key (viz. safety and efficiency
of swallowing) or else are measuring a surrogate, such as changes to
tongue muscle bulk (Carnaby-Mann 2012), rather than changes
to swallowing.
Realistic time points for assessment need to be agreed as standard
across studies for comparison and/or aggregation of data to occur.
Baseline (pre-treatment) recordings enable the effect of the initial
cancer on swallowing to be examined. Post-treatment assessment
would then enable the acute effect of (chemo)radiation to be au-
dited as an adverse event of treatment and, as data suggest that the
time to optimal recovery of swallowing is six months post-HNC
treatment completion (Perry 2003), this would be a suitable end-
point for measurement.
Other
Future trials should take into account the limitations highlighted
in this review, for example:
• report research results following the CONSORT guidelines
(CONSORT 2010);
• clearly operationalise primary and secondary outcomes;
• report adverse events;
• make protocols available online;
• use well-validated, suitable measurement tools to assess
change from therapeutic swallowing exercises in people with
head and neck cancer;
• choose time points that are meaningful for assessing change
and ensure that baseline (pre-treatment) measures are included;
• use therapeutic swallowing exercises with manageable
protocols (type, amount of exercise; dosage, timing of exercises
specified).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carnaby-Mann 2012
Methods Allocation: randomised controlled trial
Design: parallel-group
Participants Number: 58
Age (mean years): sham group: 60 ± 12.2; Pharyngocise group: 59 ± 10.4; control
group: 54 ± 11.3
Gender: sex ratio: sham group: 11 (61%) males, 7 (39%) females; Pharyngocise group:
18 (90%) males, 2 (10%) females; control (TAU) group: 15 (75%) males, 5 (25%)
females
Setting: university hospital cancer centre
Eligibility criteria:
Patients were included if they presented with:
1. Head and neck cancer of the oropharyngeal regions confirmed by the clinical history
and examination findings, with positive cross-sectional imaging studies and histopatho-
logic biopsy, excluding other pathologic factors;
2. planned external beam radiotherapy; and
3. no history of non-oral feeding for cancer-related illness and were able to undergo MRI
procedures
Exclusion criteria: nil reported
Baseline characteristics:
Tumour size (T grade): sham group median 2 (range 1 to 4); Pharyngocise group median
2 (range 1 to 4); TAU group median 2 (range 0 to 4)
Tumour site:
- Base of tongue: sham group 3; Pharyngocise group 5; TAU group 3
- Tonsil: sham group 4; Pharyngocise group 3; TAU group: 9
Tumour side:
- Left: sham group: 7; Pharyngocise group: 9; TAU group: 6
- Right: sham group 5; Pharyngocise group 6; TAU group 5
- Bilateral: sham group 6; Pharyngocise group 5; TAU group 9
Radiotherapy:
Conventional: sham group 6; Pharyngocise group 9; TAU group 9
Intensity-modulated radiotherapy (IMRT): sham group 12; Pharyngocise group 11;
TAU 11
Plus chemotherapy: sham group 6, Pharyngocise group 6; TAU group 10
Radiotherapy dose (Gy): sham group 69.2 ± 1.4; Pharyngocise group 72.5 ± 1.18; TAU
group 67.5 ± 2.5
Neck dissection (n): sham group 6; Pharyngocise group 8; TAU group 8
Left: sham group 1; Pharyngocise group 4; TAU group 3
Right: sham group 5; Pharyngocise group 4; TAU group 5
Baseline body mass index (BMI) (kg/m2): sham group 26.9 ± 1.3; Pharyngocise group 26.
8 ± 1.0; TAU 28.6 ± 1.3
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Interventions Allocation of participants: 58 head and neck cancer patients treated with chemoradio-
therapy (CRT). Interventions were conducted twice daily during CRT (up to a maxi-
mum of 6 weeks)
Intervention A: TAU (control) group:
- Attending radiation oncologist “as usual”, and treatment (if offered) consisted of su-
pervision for feeding and precautions for safe swallowing (e.g. positioning, slowed rate
of feeding) by the hospital speech pathology service
n = 20
Intervention B: standardised (sham) treatment:
- A buccal extension maneuver (“Valchuff”) and appropriate dietary modification, un-
der the direction of the study speech pathologist. The patients assigned to this group
completed the exercise for 10 repetitions over 4 cycles, each of 10 minutes’ duration.
The treatment sessions were 45 minutes in duration
n = 18
Intervention C: active swallowing exercises (Pharyngocise):
- A battery of exercises (e.g. falsetto, tongue press, hard swallow and jaw resistance/
strengthening using the Therabite JawMotion Rehabilitation System) and dietary mod-
ification, under the direction of the study speech pathologist, twice daily for the duration
of the CRT (up to a maximum of 6 weeks). The patients assigned to this condition
completed the 4 swallowing exercises as 10 repetitions over 4 cycles, each of 10 minutes’
duration. The treatment sessions were each 45 minutes in duration
n = 20
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
Primary outcome:
• Measured change in muscle size and composition, identified by T2-weighted
MRI from before to after treatment and at 6 months after randomisation
Secondary outcomes:
• Changes in the Functional Oral Intake Scale Score (FOIS)
• Changes in mouth opening
• Changes in nutritional status (reflected by patient weight)
• Occurrence of dysphagia-related complications (e.g. pneumonia,
dehydration)*
• Change from baseline to 6-week assessment in unstimulated whole saliva
production, measured using standard saliometric techniques
• Change in smell and taste perception evaluated using the University of
Pennsylvania Smell Identification Tests
Funding sources None reported
Declarations of interest Reported
Notes Single-centre study
Cross-over between treatment groups: no
Sample size calculation: based on previous reports, calculated that 60 patients would give
80% power at the 5% (two-tailed) significance level to identify this treatment effect
Language: English
Participants lost to follow-up*: TAU group (n = 5); sham group (n = 5); Pharyngocise
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group (n = 6)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported the use of computer-generated
blocked random number list
Allocation concealment (selection bias) Low risk Randomisation schedule was remotely gen-
erated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants to sham or inter-
vention arm
Blinding of outcome assessment (detection
bias)
Primary outcomes
Low risk Blinding of 2 speech pathologists to the
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants who died and were lost to fol-
low-up accounted for by data being cen-
sored for time spent in study and included
in analyses. High rate of poor compliance
reported
Selective reporting (reporting bias) Unclear risk No protocol was available. High attrition
rates.
The reported outcomes matched those
planned.
Other bias High risk Discrepancies in the numbers of partici-
pants reported between table 4 and 5 (TAU
group), which are not explained
’Dosage’ of intervention in the 2 treatment
arms was significantly greater than in the
TAUgroup and the number of sessions var-
ied between the treatment groups (high risk
of bias)
Fidelity to protocol was self-reported (high
risk of bias)
29Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kotz 2012
Methods Allocation: randomised controlled trial
Design: parallel-group
Participants Number: 26
Age (mean): total study participants: 59 years; intervention group: 57 years; control
group: 62 years
Gender: sex ratio: prophylactic swallowing exercises group 10 (77%) males, 3 (23%)
females; control group: 13 (77%) males, 3 (23%) females
Setting:Department of Otolaryngology -Head and Neck Surgery,Mount SinaiMedical
Centre, New York, USA
Eligibility criteria: newly diagnosed HNC
Exclusion criteria: patients were excluded if they had:
- a prior history of head and neck surgery including tracheostomy;
- previously undergone radiation treatment;
- a history of neurological diseases that could affect swallowing function;
- mental, cognitive, deficits mitigating against following instructions, answering ques-
tionnaires
Baseline characteristics:
Primary site of tumour:
Base of tongue: intervention group 6; control group 5
Tonsil: intervention group 4; control group 7
Glottic larynx: intervention group 0; control group 1
Nasopharynx: intervention group 1; control group 0
Oropharyngeal wall: intervention group 1; control group 0
Unknown primary: intervention group 1; control group 0
Tumour stage:
Stage 2: intervention group 1; control group 0
Stage 3: intervention group 3; control group 2
Stage 4: intervention group 9; control group 11
Chemoradiation (CRT) therapy regimen:
RT alone: intervention group: 0; control group: 1
RT + cisplatin: intervention group:8; control group: 6
RT + fluorouracil, hydroxyurea, cetuximab: intervention group: 5; control group: 6
Radiation dosage, cGy, median (range): intervention group 7000 (range: 6300 to 7200)
; control group 7200 (range 6200 to 7350)
FOIS score baseline, median (range): intervention group: 7 (range 6 to 7); control group:
7 (range 7)
PSS H&N - eating in public subscale, median (range): intervention group: 100 (range
100); control group 100 (range 100)
PSS H&N - normalcy of diet subscale, median (range): intervention group: 100 (range 50
to 100); control group: 100 (range 100)
Interventions Allocation of participants: 26 head and neck cancer patients treated with chemoradio-
therapy (CRT), consecutively recruited
Intervention A: TAU (control group)
- The control group treatment was ’standard care’ that involved referral to a head and
neck speech pathologist for swallowing assessment and treatment if dysphagia symptoms
were present after the completion of cancer treatment (n = 13)
Intervention B: prophylactic swallowing exercises
- Swallowing exercises were initiated before the start of treatment and continued for the
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duration of the CRT
This involved 5 sets of swallowing exercises counterbalanced (to avoid fatigue on the last
exercise). The exercises included effortful swallow, 2 x tongue base retraction exercises,
super-supraglottic swallowing technique and the Mendelssohn manoeuvre (n = 13)
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
The efficacy of prophylactic swallowing exercises on (1) swallowing function and (2)
swallowing-related quality of life* pre-CRT within a week after completion of CRT,
at 3, 6, 9 and 12 months after CRT
1) Swallowing function scored using Functional Oral Intake Scale (FOIS): 7-point scale
of oral dietary tolerance. Ranges from ’complete PEG dependence’ to ’tolerance of an
oral diet with no restrictions.’
2) Performance Status Scale for Head and Neck Cancer (PSS-H&N) has 3 discrete
subscales. Each subscale ranges from 0 to 100, with a higher score indicating better
function: eating in public; understandability of speech and normalcy of diet
• ’Eating in public’ subscales document a patient’s ability to share a meal with
others and notes the type of environment
• ’Understandability of speech’ subscale is to rate the degree to which the interviewer
is able to understand the patient’s speech (authors did not report this domain)
• ’Normalcy of diet’ subscale is used to assess the extent to which the patient is able
to tolerate a regular diet. This includes a ranking of 10 food categories.
Funding sources Reported none
Declarations of interest Not reported
Notes Single-centre study
Cross-over between treatment group: no
Sample size calculation: not reported
Language: English
Participants lost to follow-up: reported all patients completed the 12-month follow-
up. Intervention group: 4 patients discontinued the swallowing exercise after week 4 of
their radiation treatment and 5 additional patients discontinued the exercises after week
5 of their radiation treatment. This was due to considerable CRT-associated oral pain,
throat discomfort and fatigue
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported that the study was randomised
with no further details
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Reported blinding of personnel. Partici-
pants’ blinding not reported
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Blinding of outcome assessment (detection
bias)
Primary outcomes
Low risk Reported that the clinician who performed
the assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk There were no dropouts but a high rate
of poor compliance was reported (9 of 13
(69%) patients were unable to complete in-
tervention throughout CRT due to treat-
ment-related oral pain, throat discomfort
and/or overall fatigue)
Selective reporting (reporting bias) Low risk Protocol is available and reported outcomes
matched those planned
Other bias High risk Intervention group also had weekly speech
and language therapy sessions
Lazarus 2014
Methods Allocation: randomised clinical trial
Design: parallel-group
Participants Number: 23
Age:62years (50 to 79 years)males, 60 years female.Nodetails of control or experimental
group provided
Gender: sex ratio: 22 (96%) males, 1 (4%) female (no details of breakdown of control
and experimental group); no details provided of gender breakdown of control and inter-
vention group
Setting: multiple sites
Eligibility criteria:
- Newly diagnosed (AJCC) stage II to stage IVB oral and oropharyngeal cancer who
underwent radiotherapy ± chemotherapy
- Patients with planned neck dissection post-radiotherapy
Exclusion criteria: patients were excluded if they had:
- a history of cervical spine surgery;
- other neurosurgical procedures that might affect swallowing
Baseline characteristics: (not subdivided into groups)
Primary tumour site:
Tonsil: 11 (48%)
Base of tongue: 9 (39%)
Lateral pharyngeal wall: 2 (9%)
Soft palate: 1 (4%)
American Joint Committee on Cancer (AJCC) staging:
Stage II - 1 (4%)
Stage III - 3 (13%)
Stage IVA - 16 (70%)
Stage IVB - 3 (13%)
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Interventions Allocation of participants: 23 patients with head and neck cancer treated with radio-
therapy ± chemotherapy
Intervention A: traditional therapy (control group)
- Range of motion exercises and the Mendelsohn manoeuvre
Therapy started 1 month post-radiotherapy ± chemotherapy and was undertaken for 6
weeks (n = 11)
Intervention B: isometric tongue resistance exercise plus traditional therapy
- Active resistance in all directions - i.e. protrusion, lateralisation, elevation against tongue
depressor along with traditional exercises
Therapy started 1 month post-radiotherapy ± chemotherapy, and was performed 5 days
a week for 6 weeks, practising 5 times per day, 10 repetitions per practice session (n =
12)
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
• Maximum tongue strength;swallowing efficiency* and quality of life*
• Maximum tongue strength measured in mmHg using the Iowa Oral Performance
Instrument (IOPI)
• Swallowing function assessed using videofluoroscopy and an Oropharyngeal
Swallow Efficiency (OPSE) score*, dividing the percentage of each bolus swallowed
by the time taken to swallow it. Dysphagia was confirmed by an OPSE score of less
than 39.
• Xerostomia: evaluated using a standard xerostomia assessment. Stimulated saliva
production was quantified by the difference in the weight of a 4 x 4 folded sterile piece
of gauze before and after chewing it for 2 minutes
• Quality of life*: administered at each evaluation point using Head and Neck
Cancer Inventory (HNCI), a patient-based questionnaire with a 5-point response scale:
numerical ranking of severity (’not at all’ to ’extremely’) and frequency (’never’ to
’always’)
Funding sources NIH/NIDCD Grant 5 R03DC007497-02
Declarations of interest Reported
Notes Multiple sites study (hospitals, clinics, in New York, USA)
Both groups underwent 6 weeks of exercise starting at 1 month post-radiotherapy ±
chemotherapy
Cross-over between treatment group: no
Sample size calculation: not reported
Language: English
Participants lost to follow-up: TAU group (n = 1); intervention group (n = 4)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation table
33Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lazarus 2014 (Continued)
Allocation concealment (selection bias) Unclear risk Method of allocation was not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or clinical per-
sonnel
Blinding of outcome assessment (detection
bias)
Primary outcomes
Low risk The outcomes were analysed by a speech-
language pathologist blinded to the exper-
iment
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for participants’ loss to follow-up
partly reported
Selective reporting (reporting bias) Low risk Protocol is available. Reported outcomes
matched those as planned
Other bias Low risk
Mortensen 2015
Methods Allocation: randomised controlled trial
Design: parallel-group
Participants Number: 44
Age (mean): TAU (control) group 59 years (40 to 74 years), intervention group 58 years
(39 to 77 years)
Gender: sex ratio: treatment as usual or TAU (control) group: 17 male (85%), 3 female
(15%); intervention group: 17 male (89%), 2 female (11%)
Setting: Aarhus University Hospital, Denmark
Eligibility criteria:
- Patients aged 21 to 79 years with no prior head and neck cancer or pre-existing swal-
lowing disorder
- T2 to T4 tumour classification (Union for International Cancer Control TNM tumour
classification)
- Patients with squamous cell carcinoma (SCC) of the oral cavity, nasopharynx, orophar-
ynx, hypopharynx or larynx and who received curative treatment with either primary or
postoperative (chemo)radiation treatment
Exclusion criteria:
Patients with a history of surgery that might negatively affect swallowing
Baseline characteristics:
Primary site of tumour: larynx: 3 (16%) intervention, 4 (20%) control; pharynx: 11 (58%)
intervention, 10 (50%) control; oral cavity: 0 intervention, 4 (20%) control; unknown
primary: 5 (26%) intervention, 2 (10%) control
Tumour stage: all tumours. TAU (control) group: 15 (75%) stage IV; intervention group:
16 (84%) stage IV
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Interventions Allocation of participants: 44 participants (> 18 years) scheduled for curative chemora-
diation therapy
TAU (control) group: individual dietary advice from a dietician; VFSSs as needed and
advice to continue oral feeding
(n = 20)
Intervention group: range of motion (ROM) exercises for: jaw, tongue, pharyngeal
constrictors, laryngeal elevators, adductors. Also resistance (isometric) exercises for same
Overall 10 to 15 minutes daily practice; 10 repetitions, 3 x day, 7 days/week
Interventions were conducted before, during and after treatment
(n = 19)
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
• Change to SPSS score from VFSSs
• Other VFSS measures (aspiration/penetration*, bolus residue, cough)
• Quality of life measures* (aggregate scores from EORTC, QLQ-C30, H&N35
questionnaires)
• Tube feeding; mouth opening; compliance with protocol*
Funding sources CIRRO and the Danish Cancer Society
Declarations of interest Reported
Notes Single-centre study
Cross-over between treatment groups
Sample size calculation: not reported
Ethical approval by the local ethics committee
Trial registered in ClinicalTrials.gov, identifier NCT00332865
Language: English
Participants lost to follow-up: exclusion after randomisation (n = 5), TAU group - lost
to follow-up (n = 8), excluded from analysis (n = 2); intervention group - lost to follow-
up (n = 6), excluded from analysis (n = 3)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was done en bloc
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and occupational therapist
who delivered/oversaw treatment were not
blinded
Blinding of outcome assessment (detection
bias)
Unclear risk Radiologist who did VFSS and scored pri-
mary outcomes was blinded
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Primary outcomes Treating occupational therapist who scored
secondary outcomes was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk High rate of dropout and loss to follow-up
(in both groups)
Selective reporting (reporting bias) High risk Protocol is available and reported out-
comes matched those planned, however
time points differed (table 1 planned time
points does not match table 4 actual time
points)
Other bias High risk Higher proportion of intervention group
had concomitant chemotherapy
Log kept to document fidelity to daily ex-
ercises (self-report)
van den Berg 2014
Methods Allocation: randomised controlled trial
Design: parallel-group
Participants Number: 120
Age (mean): intervention group: 63 years (33 to 83); control group 60 years (40 to 86)
Gender: sex ratio: intervention group: 46 (77%) males, 14 (23%) female; control group:
43 (72%) males, 17 (28%) female
Setting: Radboud University Medical Centre, Netherlands
Eligibility criteria:
- Patients > 18 years of age with T2 to T4 classification (Union for International Cancer
Control TNM tumour classification) squamous cell carcinoma of the oral cavity, na-
sopharynx, oropharynx, hypopharynx or larynx
- Patients who received curative treatment with primary or postoperative (chemo)radia-
tion
Exclusion criteria:
- Patients with previous head and neck cancer treated with primary or postoperative
(chemo)radiation or surgery
- Neurological or other non-tumour related swallowing problems
- An inability to comprehend and/or an inability to answer the study questionnaires
Baseline characteristics:
Primary site of tumour:
Nasopharynx: 3 (5%) intervention group, 3 (5%) control group
Oropharynx: 20 (33%) intervention group, 16 (27%) control group
Hypopharynx: 5(9%) intervention group, 10(16%) control group
Oral cavity: 12 (20%) intervention group, 12 (20%) control group
Larynx: 20 (33%) intervention group, 19 (32%) control group
Tumour stage:
Stage II-IV tumours. Intervention group: 29 (48%) stage IV; control group (TAU): 26
(44%) stage IV
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Interventions Allocation of participants: 120 patients with head and neck cancer treatedwith (chemo)
radiation recruited; 6 withdrew consent before baseline measures taken
Intervention group: exercises delivered by speech and language therapists
a. Stretching exercises for “maximising tongue, jaw and larynx mobility”
b. Compensatory manoeuvres, such as taking smaller bites, longer chewing, more use of
liquid swallows, swallowing with more effect
c. Swallowing manoeuvres: changed head posture, supraglottic swallowing to avoid/
reduce aspiration
Same individual dietary counselling as TAU group
- Home practice: 3 times/day for at least 5 minutes
- Written and drawn instructions provided
- Intervention was weekly (for 30 weeks) during treatment; every 2 months post-CRT,
with weekly telephone monitoring (n = 60)
Control group: TAU
Individual dietary counselling by dietician weekly during treatment, focused on main-
taining/improving patient’s energy and protein intake (n = 60)
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
Primary outcome:
• Change to PSS-H&N (normalcy of diet) score. Score 100 = optimal.
• Change to NFIS-HN-F score (normalcy of food intake scale for head and neck -
dietetic part). Based on data from a 2-day food diary.
Secondary outcomes:
• Dysphagia severity (NFIS-HN-L score (clinician-rated oral intake scale)) and M-
DADI (self-rated inventory)
• Swallowing capacity; velocity and volume tests
• Social eating: PSS-H&N ’eating in public’ scale rated
• Nutritional status: body weight was measured and relative weight change was
calculated, as was BMI
Data collected at 0 (baseline, first week of treatment); then week 6 (last week treatment)
, 10 (1 month post-treatment), 18 (3 months post-treatment) and 30 (6 months post-
treatment)
Funding sources Fresenius Kabi Netherlands
Declarations of interest Not reported
Notes Sample size: power calculation at 80% with an estimated withdrawal rate of 20%
Ethics approval by the Radboud University ethics committee (ABR: 28638.091.09)
Trial protocol was registered on ClinicalTrials.gov (FOCISD: NCT0110980)
Language: English
Participants lost to follow-up: TAU group (n = 20); intervention group (n = 19)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation with 1:1 ratio using a com-
puter-controlled process
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients, dieticians and speech and lan-
guage pathologists were all aware of the
treatment allocation
Blinding of outcome assessment (detection
bias)
Primary outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk No results on BMI at follow-up although
change of weight reported
Selective reporting (reporting bias) Unclear risk Protocol is available but detail on measure-
ment of outcome (BMI) is unclear
Other bias High risk Intervention group also had weekly speech
and language therapy sessions
van der Molen 2011
Methods Allocation: randomised clinical trial
Design: parallel-group
Participants Number: 55
Age (mean): 56 years (37 to 78); control: 57 years (32 to 75)
Gender: sex ratio: TheraBite jaw motion rehabilitation group: 23 (96%) males, 1 (4%)
female; standard group: jaw ROM exercises group: 16 (64%) males, 9 (36%) females
Setting: Netherlands Cancer Institute
Eligibility criteria:
- Squamous cell carcinoma
- Oral cavity, oropharynx, hypopharynx, larynx and nasopharynx tumours
- Stage III-IV head and neck cancers
- Primary treatment with concomitant chemoradiotherapy (CCRT) with curative intent
- Written informed consent
Exclusion criteria:
- Unable to comprehend the function and use of the rehabilitation exercises and device
(e.g. Alzheimer’s disease, Korsakov’s disease)
- Physically unfit to use a rehabilitation device (e.g. neurological deficit)
Baseline characteristics:
Primary site of tumour:
Nasopharynx: 3 (13%) intervention group, (16%) control group
Oral cavity/oropharynx: 12 (50%) intervention group, 12 (47%) control group
Larynx/hypopharynx: 9 (37%) intervention group, 9 (37%) control group
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Tumour stage:
Stage III-IV tumours
Stage III: intervention group: 7 (29%) control group: 9 (36%)
Stage IV: intervention group: 17 (71%), control group: 16 (64%)
Interventions Allocation of participants: 55 head and neck cancer patients treated with concomitant
chemoradiotherapy (CRT)
Intervention A: standard care (control group)
- Jaw ROM exercise: 3 times daily; 3 repetitions each
- Strengthening exercises: 3 times daily; 5 repetitions each (effortful swallow, Masako
manoeuvre, super-supra-glottic swallow) (n = 28)
Intervention B:
- Therabite jaw motion rehabilitation system, 3 times daily, 3 repetitions (slow mouth
opening, swallowing with tongue elevated to palate and 50%maximummouth opening)
(n = 27)
Interventions began 2 weeks before CRT and continued throughout treatment
Use of additional interventions: none
Outcomes NB: Specific outcomes of interest to this review are bolded and marked with an asterisk
Patients were assessed 2 weeks before the onset of CCRT and approximately 10 weeks
after completing same
• Function outcomes: assessed using videofluoroscopy (to rate laryngeal
penetration, laryngeal aspiration*, presence of residue)
• Maximum inter-incisor mouth opening (MIO)
• Occurrence of trismus
• Weight changes
• Body mass index (BMI)
• Nutrition - the Functional Oral Intake Scale (FOIS)
• Quality of life* questionnaire
• Pain assessment - visual analogue scale (VAS)
Funding sources Part of study was supported by an unrestricted research grant from Atos Medical, Horby,
Sweden
Declarations of interest Not reported
Notes Single-centre study
All patients received 100 mg/m2cisplatin as a 40-minute IV infusion on days 1, 22 and
43. Intensity-modulated radiotherapy (IMRT) of 70Gy in 35 fractions was administered
over 7 weeks starting concurrently with chemotherapy
Cross-over between treatment groups: not reported
Sample size calculation: no details
Language: English
Participants lost to follow-up: TAU group (n = 3); intervention group (n = 3)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomised centrally by computer using
blocks of 6 and stratified by tumour site
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not reported
Blinding of outcome assessment (detection
bias)
Primary outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up reported and explained
but poor compliance with treatment re-
ported; only 7 patients (17%) practised
daily throughout CRT
Selective reporting (reporting bias) Low risk Protocol is available and reported outcomes
matched those planned
Other bias High risk Patients in control group practised signifi-
cantlymore days than patients in treatment
group (P = 0.05; mean 59 and 41 days re-
spectively)
Compliance was assessed by use of “famil-
iarity with exercise” score but familiarity
does not necessarily equate to compliance
AJCC: American Joint Committee on Cancer
BMI: body mass index
CCRT: concomitant chemoradiotherapy
CRT: chemoradiotherapy
EORTC: European Organisation for Research and Treatment of Cancer
FOIS: Functional Oral Intake Scale
HNC: head and neck cancer
HNCI: Head and Neck Cancer Inventory
IOPI: Iowa Oral Performance Instrument
IV: intravenous
LENT/SOMA scales: Late Effects Normal Tissue (LENT)/Subjective, Objective, Management, Analytic (SOMA) scales
M-DADI: MD Anderson Dysphagia Inventory
MRI: magnetic resonance imaging
N/A: not applicable
NFIS-HN-F: Normalcy of Food Intake Scale for Head and Neck - Dietetic Part
NFIS-HN-L: Normalcy of Food Intake Scale for Head and Neck- Logopedic Part
NPC: nasopharyngeal carcinoma
OPSE: Oropharyngeal Swallowing Efficiency
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PEG: percutaneous endoscopic gastroscopy
PSS-H&N: Performance Status Scale for Head and Neck
ROM: range of motion
RT: radiotherapy
SCC: squamous cell carcinoma
SPSS: Statistical Package for the Social Sciences
TAU: treatment as usual
TNM: tumour, node, metastasis
VAS: visual analogue scale
VFSS: videofluoroscopic swallowing study
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Carroll 2008 No randomisation
Tang 2011 Randomised controlled trial but exercises directed at rehabilitation, not prevention, of dysphagia
Virani 2013 No randomisation
Zhen 2012 No randomisation
Characteristics of ongoing studies [ordered by study ID]
Barretos Cancer Hospital 2015
Trial name or title Swallowing intervention during radiochemotherapy on head and neck cancer (Swallowing-1)
Methods Randomised clinical trial phase II; single-centre
Participants Age for study: < 18 years
Gender: both
n = 80 patients with advanced oropharynx, larynx and hypopharynx cancer diagnoses from Barretos Cancer
Hospital, proposed for neoadjuvant chemotherapy followed by radiotherapy combined with chemotherapy
Inclusion criteria:
• Head and neck squamous cell carcinoma
• Indication for the protocol treatment of neoadjuvant chemotherapy followed by radiotherapy
concomitant to chemotherapy
• Oropharynx, larynx and hypopharynx advanced cancer (T3 or T4), classified as resectable
• 18 years old or older
• Informed consent signed before any specific procedure
Exclusion criteria:
• Previous head and neck surgery
• Previous radiotherapy or chemotherapy
• Previous history of neoplasia, excepted for in situ carcinoma of endometrial (uterine) cancer, skin basal
cell or squamous cell carcinoma
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• Severe laryngeal aspiration during all consistencies swallowing evaluated thought videofluoroscopy
• Patients with cognitive deficit who could not comprehend the speech pathology intervention
Interventions 2 groups: control group (no intervention) and speech pathology therapy (swallowing exercise) group
Procedure: pre-, during and post-treatment swallowing exercises given by speech pathologist(s)
Outcomes Primary: swallowing function (time frame: up to 6 months after concurrent phase). Designated as safety
issue: No 1
Measures: self-reporting swallowing questionnaire, clinical swallowing examination; VFSS or modified bar-
ium swallow (MBS), and the MD Anderson Dysphagia Inventory (MDADI)
Starting date July 2012
Completed: November 2014 (final data collection date for primary outcome measure)
Contact information Barretos Cancer Hospital, Barretos, São Paulo, Brazil, 14780400
Notes To evaluate and compare the swallowing and quality of life of a patient group undergoing a speech pathology
therapy (intervention) and a control group (no intervention)
Fredslund 2015
Trial name or title Pre-habilitation of patients with head and neck cancer SYNK
Methods RCT; efficacy study, single-centre
Participants Age: minimum: 18 years; maximum: N/A
Gender: both
Inclusion criteria:
- Histological proven cancer in one or more of the following areas: larynx, pharynx, cavi oris, cavi nasi, salivary
glands, thyroid, sinuses, head and neck cancer; metastases to the neck lymph nodes, or unknown primary
tumour
- Set to curative radiotherapy with or without concurrent chemotherapy for treatment of cancer in the head
and neck region in accordance with the Danish Head and Neck Cancer Group (DAHANCA) guidelines
- Fully self-reliant
- Danish skills, oral and written
- Informed consent
Exclusion criteria:
- Previously received treatment for head and neck cancer (radiotherapy, chemotherapy and/or surgery)
- Pregnancy
- ECOG performance status > 2
- Presence of psychological, family, sociological or geographical issues that could prevent the patient from
completing the intervention
- Simultaneous or previous illness or conditions that could prevent the patient being able to complete the
intervention
Sample size: 240
Interventions Behavioural: swallowing therapy and resistance training
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Fredslund 2015 (Continued)
Outcomes Primary: swallowing function measured by penetration aspiration scale (PAS) during a Fibre-Endoscopic
Evaluation of Swallowing (FEES)
(Time frame: participants will be followed up until 12months after they finalise their radiotherapy, an expected
average of 58 weeks from baseline)
Secondary:
- Anxiety by Symptom Check List (SCL-92) Anxiety subscale
- Body composition by bioimpedance
- Depression by Major Depression Inventory (MDI)
- Health-related quality of life by the EuropeanOrganisation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire (QLQ)-30 and EORTC QLQ-H&N35
- Level of fatigue by the EORTC QLQ-C30 3-point fatigue subscale
- Level of oral intake by Functional Oral Intake Scale (FOIS)
- Maximal inter-incisal distance (MID) by Therabite range of motion (ROM) scale
- Pain by numerical rating scale (NRS)
- Performance Status by Eastern Cooperative Oncology Group (ECOG) performance scale
- Physical strength by 30 seconds Sit to Stand (STS) test
- Subjective symptoms of dysphagia by EAT-10 (eating assessment tool)
- Weight loss by body weight
Starting date May 2015
Contact information Sara V Fredslund, MSc
Danish Cancer Society
Rigshospitalet, Denmark
sara.vinther.fredslund@regionh.dk
Ph: 0045 51908661
Notes Efficacy study, intervention model: parallel assignment, masking: single blind (outcomes assessor)
Primary purpose: supportive care
Primary sponsor: Irene Wessel
Secondary sponsors:
• Danish Association of Occupational Therapists
• Danish Cancer Society
• Rigshospitalet, Denmark
Identifiers:
H-2-2014-074
R108-A6969-14-S31
Govender 2014
Trial name or title SIP SMART: Swallowing intervention package - self monitoring, assessment & rehabilitation training
Methods RCT
Participants Inclusion criteria from qualitative interviews:
1. Patients who have completed treatment for advanced head and neck cancer
2. A minimum of 3 months post-treatment
3. Had input from a speech and language therapist as part of their cancer care
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Govender 2014 (Continued)
4. Able to provide informed consent and willing to be interviewed for 40 minutes
5. Proficiency in English satisfactory for interview/participation in intervention
6. Aged 18 and above
Preliminary testing: feasibility study
1. Patients with newly diagnosed stage III and stage IV cancer of the oral cavity or pharynx
2. Discussed at University College London Hospitals head and neck multidisciplinary team and planned for
curative treatment via surgery and/or chemoradiotherapy or combination thereof
3. Able to provide informed consent
4. Proficiency in English satisfactory to participate/engage in the intervention
5. Aged 18 and above
Exclusion criteria:
1. Patients who are mid treatment or those receiving palliation
2. Patients who have been treated solely by non-standard treatment i.e. not surgery, radiotherapy, chemora-
diotherapy or combinations thereof. Patients treated by chemotherapy, brachytherapy, photodynamic therapy
alone will be ineligible
3. Patients who are considered vulnerable or unable to provide informed consent
4. Patients with brain tumours and other primary sites not within the head and neck
Sample size: 45
Interventions The study design is informed by the Medical Research Council complex intervention guidelines
The development phasewill be informedby literature reviews, in-depth patient interviews andpapermodelling
of the intervention
The preliminary testing phase - feasibility using stratified block randomisation
1:1 allocation to treatment or usual care group
Followed up for 6 months from date of surgery (if surgery only) or date of first radiotherapy treatment (if
radiotherapy or combined modality treatment)
Outcomes Primary:
1. MDADI swallowing outcome; time point(s): pre-treatment, post-treatment at 1, 3, 6 months
2. Modified barium swallow (VFSS) done at 6 months
Secondary:
1. FACT-QOL; time point(s): pre-treatment, post-treatment 1, 3, 6 months
2. PSS-H&N - normalcy of diet, time point(s): pre-treatment, post-treatment at 1, 3, 6 months
Starting date 6 October 2014
End date: 1 September 2016
Contact information Ms Roganie Govender
Head and Neck Cancer Centre
First Floor East, University College Hospital
250 Euston Road
London NW1 2PQ
UK
roganie.govender@uclh.nhs.uk
Notes Trial setting: hospitals
Funders: NIHR (UK)
Protocol/serial number: 17043
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van Nuffelen 2014
Trial name or title Tongue strengthening exercises in head and neck cancer patients: does level of resistance matter?
Methods Single-centre interventional RCT
Participants Participant inclusion criteria:
1. Head and neck cancer patients previously treated with chemoradiotherapy
2. Men and women older than 18, without cognitive, language, motor, hearing or visual deficits that could
interfere with the correct execution of the training.
3. Chronic dysphagia (i.e. present for at least 1 month and no earlier than 6 months after the last day of
radiation treatment), primarily related to reduced tongue strength
4. Score 1 or higher for the BRACS items ‘base of tongue’ and/or ‘valleculae’ at baseline judged by an
experienced clinician
Inclusion criteria
1. Head and neck cancer patients previously treated with chemoradiotherapy
2. Men and women older than 18, without cognitive, language, motor, hearing or visual deficits that could
interfere with the correct execution of the training
3. Chronic dysphagia (i.e. present for at least 1 month and no earlier than 6 months after the last day of
radiation treatment), primarily related to reduced tongue strength
4. Score 1 or higher for the BRACS items ‘base of tongue’ and/or ‘valleculae’ at baseline judged by an
experienced clinician
Exclusion criteria:
1. History of major oral or head and neck surgery and neurological disorders with an impact on oral function
and/or swallowing (amongst others stroke, traumatic brain injury, Parkinson’s disease, amyotrophic lateral
sclerosis)
2. Concurrent oral motor exercises or swallowing manoeuvres to improve swallowing are not allowed during
the study period
Sample size: 45 (15 per group)
Interventions Tongue strengthening exercises
The effect of tongue strengthening exercises will depend upon the level of resistance
Outcomes Primary outcome measures:
1. Tongue strength measurements: maximum isometric pressures (expressed as kPa) anterior and posterior
The primary measures are evaluated prior to (max 1 week in advance), during (after 4 weeks of therapy), after
8 weeks of therapy and at 4 and 8 weeks post-treatment
Secondary outcome measures:
1. Swallowing function: the swallowing function will be evaluated using a comprehensive fibre-optic endo-
scopic evaluation of swallowing (FEES) examination; the Mann Assessment of Swallowing Ability-Cancer
(MASA-C); the Functional Oral Intake Scale (FOIS) and a self-evaluation. For the latter a 100 mm visual
analogue scale is used with the ends defined as ‘I can’t swallow’ (0) and ‘I don’t have any swallowing difficulties’
(100) respectively. Both the FEES and MASA-C are conducted with 4 different bolus types: 5 and 10 ml
of thin liquid, and 5 and 10 ml of yogurt. Each bolus type is administered 3 times. Outcome measures for
FEES are the Penetration-Aspiration Scale, the Carnaby-Videofluoroscopic Examination (C-VFE) scales for
dysphagia and aspiration; the Pooling-Score and the Boston Residue and Clearance Scale (BRACS)
2. Quality of life: swallowing-related quality of life will be surveyed by means of the Dutch Swallowing
Quality-of-Life Questionnaire (DSWAL-QoL) and the Dysphagia Handicap Index (DHI)
The secondary outcome measures are evaluated prior to (max 1 week in advance), during (after 4 weeks of
therapy), after 8 weeks of therapy and at 4 and 8 weeks post-treatment
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van Nuffelen 2014 (Continued)
Starting date March 2014
End date: December 2016
Contact information Prof Gwen Van Nuffelen
Wilrijkstraat 10
Edegem (Antwerp)
2650
Belgium
gwen.van.nuffelen@uza.be
Notes Hospitals
Protocol/serial number: NKR 2014 01
Single-centre interventional RCT
Recruiting
BRACS: Boston Residue and Clearance Scale (BRACS)
ECOG: Eastern Cooperative Oncology Group
FACT: Functional Assessment of Cancer Therapy
MDADI: MD Anderson Dysphagia Inventory
N/A: not applicable
PSS-H&N: Performance Status Scale for Head and Neck
QOL: quality of life
RCT: randomised controlled trial
VFSS: videofluoroscopic swallowing study
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D A T A A N D A N A L Y S E S
Comparison 1. Tongue exercises + traditional therapy versus traditional therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swallowing function (OPSE) 1 16 Mean Difference (IV, Fixed, 95% CI) -8.06 [-25.37, 9.25]
Comparison 2. Swallow therapy versus treatment as usual (TAU)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swallowing velocity (ml/sec) 1 120 Mean Difference (Fixed, 95% CI) -2.0 [-5.30, 1.30]
2 Swallowing volume, ml 1 120 Mean Difference (Fixed, 95% CI) 5.9 [-1.10, 12.90]
3 Weight change 1 120 Mean Difference (Fixed, 95% CI) 1.34 [-0.46, 3.14]
4 Dysphagia severity 1 120 Mean Difference (Fixed, 95% CI) -0.1 [-0.50, 0.30]
Comparison 3. Pharyngocise versus sham care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swallowing ability (VFE) 1 38 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.24, -0.04]
2 Weight loss (> 10%) 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.22, 1.71]
Comparison 4. Pharyngocise versus treatment as usual (TAU)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swallowing ability - VFE 1 40 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.09, 0.07]
2 Weight loss (> 10%) 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.22, 1.71]
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Comparison 5. Sham exercises versus treatment as usual (TAU)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swallowing ability (VFE) 1 38 Mean Difference (IV, Fixed, 95% CI) 0.13 [0.05, 0.21]
Analysis 1.1. Comparison 1 Tongue exercises + traditional therapy versus traditional therapy, Outcome 1
Swallowing function (OPSE).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 1 Tongue exercises + traditional therapy versus traditional therapy
Outcome: 1 Swallowing function (OPSE)
Study or subgroup Tongue exercises TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lazarus 2014 (1) 8 46.5 (14.85) 8 54.56 (20.08) 100.0 % -8.06 [ -25.37, 9.25 ]
Total (95% CI) 8 8 100.0 % -8.06 [ -25.37, 9.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours TAU Favours tongue exercises
(1) The baseline was not balance, therefore these final scores are not reliable.
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Analysis 2.1. Comparison 2 Swallow therapy versus treatment as usual (TAU), Outcome 1 Swallowing
velocity (ml/sec).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 2 Swallow therapy versus treatment as usual (TAU)
Outcome: 1 Swallowing velocity (ml/sec)
Study or subgroup Swallow therapy TAU Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van den Berg 2014 60 60 -2 (1.6837) 100.0 % -2.00 [ -5.30, 1.30 ]
Total (95% CI) 60 60 100.0 % -2.00 [ -5.30, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours TAU Favours swallowing therapy
Analysis 2.2. Comparison 2 Swallow therapy versus treatment as usual (TAU), Outcome 2 Swallowing
volume, ml.
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 2 Swallow therapy versus treatment as usual (TAU)
Outcome: 2 Swallowing volume, ml
Study or subgroup Swallow therapy TAU Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van den Berg 2014 60 60 5.9 (3.5715) 100.0 % 5.90 [ -1.10, 12.90 ]
Total (95% CI) 60 60 100.0 % 5.90 [ -1.10, 12.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours TAU Favours swallowing therapy
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Analysis 2.3. Comparison 2 Swallow therapy versus treatment as usual (TAU), Outcome 3 Weight change.
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 2 Swallow therapy versus treatment as usual (TAU)
Outcome: 3 Weight change
Study or subgroup TAU Swallowing therapy Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van den Berg 2014 60 60 1.34 (0.9184) 100.0 % 1.34 [ -0.46, 3.14 ]
Total (95% CI) 60 60 100.0 % 1.34 [ -0.46, 3.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours TAU Favours swallowing therapy
Analysis 2.4. Comparison 2 Swallow therapy versus treatment as usual (TAU), Outcome 4 Dysphagia
severity.
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 2 Swallow therapy versus treatment as usual (TAU)
Outcome: 4 Dysphagia severity
Study or subgroup Swallowing therapy TAU Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
van den Berg 2014 (1) 60 60 -0.1 (0.2041) 100.0 % -0.10 [ -0.50, 0.30 ]
Total (95% CI) 60 60 100.0 % -0.10 [ -0.50, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours TAU Favours swallowing therapy
(1) Reported lower 95% CI of -5.2 in paper but presumed error.
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Analysis 3.1. Comparison 3 Pharyngocise versus sham care, Outcome 1 Swallowing ability (VFE).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 3 Pharyngocise versus sham care
Outcome: 1 Swallowing ability (VFE)
Study or subgroup Pharyngocise Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carnaby-Mann 2012 20 0.2 (0.16) 18 0.34 (0.16) 100.0 % -0.14 [ -0.24, -0.04 ]
Total (95% CI) 20 18 100.0 % -0.14 [ -0.24, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours Pharyngocise Favours sham
Analysis 3.2. Comparison 3 Pharyngocise versus sham care, Outcome 2 Weight loss (> 10%).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 3 Pharyngocise versus sham care
Outcome: 2 Weight loss (> 10%)
Study or subgroup Pharyngocise Sham Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carnaby-Mann 2012 4/14 6/13 100.0 % 0.62 [ 0.22, 1.71 ]
Total (95% CI) 14 13 100.0 % 0.62 [ 0.22, 1.71 ]
Total events: 4 (Pharyngocise), 6 (Sham)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Pharyngocise Favours sham
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Analysis 4.1. Comparison 4 Pharyngocise versus treatment as usual (TAU), Outcome 1 Swallowing ability -
VFE.
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 4 Pharyngocise versus treatment as usual (TAU)
Outcome: 1 Swallowing ability - VFE
Study or subgroup Pharyngocise TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carnaby-Mann 2012 20 0.2 (0.16) 20 0.21 (0.09) 100.0 % -0.01 [ -0.09, 0.07 ]
Total (95% CI) 20 20 100.0 % -0.01 [ -0.09, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Pharyngocise Favours TAU
Analysis 4.2. Comparison 4 Pharyngocise versus treatment as usual (TAU), Outcome 2Weight loss (> 10%).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 4 Pharyngocise versus treatment as usual (TAU)
Outcome: 2 Weight loss (> 10%)
Study or subgroup Pharyngocise TAU Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carnaby-Mann 2012 4/14 6/13 100.0 % 0.62 [ 0.22, 1.71 ]
Total (95% CI) 14 13 100.0 % 0.62 [ 0.22, 1.71 ]
Total events: 4 (Pharyngocise), 6 (TAU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Pharyngocise Favours TAU
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Analysis 5.1. Comparison 5 Sham exercises versus treatment as usual (TAU), Outcome 1 Swallowing ability
(VFE).
Review: Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Comparison: 5 Sham exercises versus treatment as usual (TAU)
Outcome: 1 Swallowing ability (VFE)
Study or subgroup Sham exercises TAU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carnaby-Mann 2012 18 0.343 (0.16) 20 0.21 (0.09) 100.0 % 0.13 [ 0.05, 0.21 ]
Total (95% CI) 18 20 100.0 % 0.13 [ 0.05, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours TAU Favours sham
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE EMBASE (Ovid)
#1 MeSH descriptor: [Oropharyngeal
Neoplasms] explode all trees
#2 MeSH descriptor: [Head and Neck
Neoplasms] this term only
#3 MeSH descriptor: [Otorhinolaryngo-
logic Neoplasms] explode all trees
#4 MeSH descriptor: [Neoplasms] explode
all trees
#5 cancer* or carcinoma* or neoplas* or
tumor* or tumour* or malignan* or SCC
#6 #4 or #5
#7 MeSH descriptor: [Oropharynx] ex-
plode all trees
#8 oropharyn* or mesopharyn* or tonsil*
or (head near/3 neck) or “tongue base”
1 exp Oropharyngeal Neoplasms/
2 “Head and Neck Neoplasms”/
3 exp Otorhinolaryngologic Neoplasms/
4 exp Neoplasms/
5 (cancer* or carcinoma* or neoplas* or tu-
mor* or tumour* or malignan* or SCC).tw
6 4 or 5
7 exp Oropharynx/
8 (oropharyn* or mesopharyn* or tonsil*
or (head adj3 neck) or “tongue base”).tw
9 7 or 8
10 6 and 9
11 (HNSCC or SCCHN or OP-SCC or
OPSCC).tw.
12 1 or 2 or 3 or 10 or 11
1 exp Oropharyngeal Neoplasms/
2 “Head and Neck Neoplasms”/
3 exp Otorhinolaryngologic
Neoplasms/
4 exp Neoplasms/
5 (cancer* or carcinoma* or neoplas* or tu-
mor* or tumour* or malignan* or SCC).
tw.
6 4 or 5
7 exp Oropharynx/
8 (oropharyn* ormesopharyn* or tonsil* or
(head adj3 neck) or “tongue base”).tw.
9 7 or 8
10 6 and 9
11 (HNSCC or SCCHN or OP-SCC or
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(Continued)
#9 #7 or #8
#10 #6 and #9
#11 HNSCC or SCCHN or OP-SCC or
OPSCC
#12 #1 or #2 or #3 or #10 or #11
#13 MeSH descriptor: [Deglutition] ex-
plode all trees
#14MeSH descriptor: [Deglutition Disor-
ders] this term only
#15 swallow* or deglutit* or dysphag*
#16 #13 or #14 or #15
#17 MeSH descriptor: [Exercise Therapy]
explode all trees
#18MeSH descriptor: [Isometric Contrac-
tion] explode all trees
#19 MeSH descriptor: [Behavior Therapy]
explode all trees
#20 (swallow* or deglutit* or dysphag* or
neuromuscular or mendelsohn or masako
or “neuro muscular”) near/3 (exercis* or
maneuver* or manoeuvre* or manoeuver*
or technique* or treatment* or strateg* or
rehab* or therap*)
#21 isometric or IOPI or “iowa oral
pressure instrument*” or pharyngocise or
OPSE or “oropharyngeal swallowing effi-
ciency”
#22 nmt or “lingual exercis*” or “effortful
swallow*” or “supraglottic swallow” or “su-
per glottic swallow*” or “supra glottic swal-
low*”
#23 (tongue or BOT) near/3 (“range of
motion” or ROM or resistance or strength*
or holding)
#24 (voluntary near/3 (control or maneu-
ver* or manoeuvre* or manoeuver*)) or
“bearing down” or “progressive resistance”
or “behav* management” or (exercis* near/
3 (therap* or regime)) or “therapeutic tech-
niq*” or “behav* therap*” or “larygeal ele-
vat*”
#25 #17 or #18 or #19 or #20 or #21 or #
22 or #23 or #24
#26 #25 and #16
#27MeSH descriptor: [Deglutition Disor-
ders] explode all trees and with qualifier(s):
[Prevention & control - PC, Rehabilitation
- RH, Therapy - TH]
#28 #26 or #27
13 exp Deglutition/
14 Deglutition Disorders/
15 (swallow* or deglutit* or dysphag*).tw.
16 13 or 14 or 15
17 exp Exercise Therapy/
18 exp Isometric Contraction/
19 exp Behavior Therapy/
20 ((swallow* or deglutit* or dysphag* or
neuromuscular or mendelsohn or masako
or “neuro muscular”) adj3 (exercis* or ma-
neuver* or manoeuvre* or manoeuver* or
technique* or treatment* or strateg* or re-
hab* or therap*)).tw
21 (isometric or IOPI or “iowaoral pressure
instrument*” or pharyngocise or OPSE or
“oropharyngeal swallowing efficiency”).tw
22 (nmt or “lingual exercis*” or “effortful
swallow*” or “supraglottic swallow” or “su-
per glottic swallow*” or “supra glottic swal-
low*”).tw
23 ((tongue or BOT) adj3 (“range of mo-
tion” or ROM or resistance or strength* or
holding)).tw
24 ((voluntary adj3 (control or maneu-
ver* or manoeuvre* or manoeuver*)) or
“bearing down” or “progressive resistance”
or “behav* management” or (exercis* adj3
(therap* or regime)) or “therapeutic tech-
niq*” or “behav* therap*” or “larygeal ele-
vat*”).tw
25 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24
26 16 and 25
27 exp Deglutition Disorders/pc, rh, th
[Prevention & Control, Rehabilitation,
Therapy]
28 26 or 27
29 12 and 28
OPSCC).tw.
12 1 or 2 or 3 or 10 or 11
13 exp swallowing/
14 dysphagia/
15 (swallow* or deglutit* or dysphag*).
tw.
16 13 or 14 or 15
17 exp Exercise Therapy/
18 exp Isometric Contraction/
19 exp Behavior Therapy/
20 ((swallow* or deglutit* or dysphag* or
neuromuscular or mendelsohn or masako
or “neuro muscular”) adj3 (exercis* or ma-
neuver* or manoeuvre* or manoeuver* or
technique* or treatment* or strateg* or re-
hab* or therap*)).tw.
21 (isometric or IOPI or “iowaoral pressure
instrument*” or pharyngocise or OPSE or
“oropharyngeal swallowing efficiency”).tw
22 (nmt or “lingual exercis*” or “effortful
swallow*” or “supraglottic swallow” or “su-
per glottic swallow*” or “supra glottic swal-
low*”).tw.
23 ((tongue or BOT) adj3 (“range of mo-
tion” or ROM or resistance or strength* or
holding)).tw.
24 ((voluntary adj3 (control or maneu-
ver* or manoeuvre* or manoeuver*)) or
“bearing down” or “progressive resistance”
or “behav* management” or (exercis* adj3
(therap* or regime)) or “therapeutic tech-
niq*” or “behav* therap*” or “larygeal ele-
vat*”).tw.
25 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24
26 16 and 25
27 exp dysphagia/pc, rh, th [Prevention,
Rehabilitation, Therapy]
28 26 or 27
29 12 and 28
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#29 #12 and #28
CINAHL (EBSCO) Web of Science (Web of Knowledge) Trial registries
S29 S11 AND S28
S28 S25 OR S26 OR S27
S27 (MH “Swallowing Therapy”)
S26 (MH“DeglutitionDisorders/PC/RH/
TH”)
S25 S15 AND S24
S24 S16ORS17OR S18ORS19OR S20
OR S21 OR S22 OR S23
S23 TX (voluntary n3 (control or maneu-
ver* or manoeuvre* or manoeuver*)) or
“bearing down” or “progressive resistance”
or “behav* management” or (exercis* n3
(therap* or regime)) or “therapeutic tech-
niq*” or “behav* therap*” or “larygeal ele-
vat*”
S22 TX (tongue or BOT) n3 (“range of
motion” or ROM or resistance or strength*
or holding)
S21 TX nmt or “lingual exercis*” or “ef-
fortful swallow*” or “supraglottic swallow”
or “super glottic swallow*” or “supra glottic
swallow*”
S20 TX isometric or IOPI or “iowa oral
pressure instrument*” or pharyngocise or
OPSE or “oropharyngeal swallowing effi-
ciency”
S19 TX (swallow* or deglutit* or dys-
phag* or neuromuscular or mendelsohn or
masako or “neuro muscular”) n3 (exercis*
or maneuver* or manoeuvre* or manoeu-
ver* or technique* or treatment* or strateg*
or rehab* or therap*)
S18 (MH “Behavior Therapy+”)
S17 (MH “Isometric Contraction”)
S16 (MH “Therapeutic Exercise+”)
S15 S12 OR S13 OR S14
S14 TX swallow* or deglutit* or dysphag*
S13 (MH “Deglutition Disorders”)
S12 (MH “Deglutition”)
S11 S1 OR S2 OR S9 OR S10
S10 TX HNSCC or SCCHN or OP-SCC
or OPSCC
S9 S5 AND S8
S8 S6 OR S7
S7 TX oropharyn* or mesopharyn* or ton-
#1 TOPIC: (cancer* or carcinoma* or neo-
plas* or tumor* or tumour* or malignan*
or SCC)
#2 TOPIC: (oropharyn* or mesopharyn*
or tonsil* or (head near/3 neck) or “tongue
base”)
#3 #2 AND #1
#4 TOPIC: (HNSCC or SCCHN or OP-
SCC or OPSCC)
#5 #4 OR #3
#6 TITLE: (swallow* or deglutit* or dys-
phag*)
#7 TITLE: ((neuromuscular or mendel-
sohn or masako or “neuro muscular”) and
(exercis* or maneuver* or manoeuvre* or
manoeuver* or technique* or treatment* or
strateg* or rehab* or therap*))
#8TITLE: (isometric or IOPI or “iowa oral
pressure instrument*” or pharyngocise or
OPSE or “oropharyngeal swallowing effi-
ciency”)
#9 TITLE: (nmt or “lingual exercis*” or
“effortful swallow*” or “supraglottic swal-
low” or “super glottic swallow*” or “supra
glottic swallow*”)
#10TITLE: ((tongue or BOT) and (“range
of motion” or ROM or resistance or
strength* or holding))
#11 TITLE: ((voluntary and (control or
maneuver* or manoeuvre* or manoeuver*)
) or “bearing down” or “progressive resis-
tance” or “behav* management” or (ex-
ercis* and (therap* or regime)) or “ther-
apeutic techniq*” or “behav* therap*” or
“larygeal elevat*”)
#12 #11 OR #10 OR #9 OR #8 OR #7
OR #6
#13 #12 AND #5
ICTRP
Title: swallow* OR deglutit* OR dysphag*
ClinicaTrials.gov
(swallow* OR deglutit* OR dysphag*)
AND (HNSCC OR SCCHN OR OP-
SCC OR OPSCC OR oropharyn* OR
mesopharyn* OR tonsil* OR (head AND
neck) OR “tongue base”)
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sil* or (head n3 neck) or “tongue base”
S6 (MH “Oropharynx+”)
S5 S3 OR S4
S4TXcancer* or carcinoma* or neoplas* or
tumor* or tumour* or malignan* or SCC
S3 (MH “Neoplasms+”)
S2 (MH “Otorhinolaryngologic Neo-
plasms+”)
S1 (MH “Head and Neck Neoplasms+”)
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